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SUMMARY   
 
Introduction: 
Occupational therapists (OTs) play an important role in evaluating the cognitive and 
functional abilities of older adults with mild cognitive impairment (MCI) in the acute 
hospital setting. Cognitive screening tools such as the Montreal Cognitive 
Assessment (MoCA) and the Addenbrooke’s Cognitive Examination (ACE-III) are 
regularly administered by acute hospital OTs to assist in predicting the functional 
capacities of individuals with MCI. However findings from clinical practice show 
that performance on cognitive screening tools is not always consistent with 
functional task performance.  
 
Aims and Objectives: 
The aim of the research was to explore the relationship between cognitive test 
performance and instrumental activity of daily living (IADL) function in older adults 
with MCI in the acute hospital setting. The objectives of the study were to determine 
which cognitive screening tool (MoCA or ACE-III) was most strongly related to 
IADL function, to determine the relationship between individual cognitive 
subdomains of the MoCA/ACE-III and IADL function and to explore the influence 
of various cognitive and demographic variables on IADL function. 
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Methods:  
Forty older adults with MCI were recruited from an acute hospital setting for this 
cross-sectional study. All participants completed cognitive screening tests (MoCA 
and ACE-III) and an objective measure of everyday functioning (Executive Function 
Performance Test, EFPT). Correlation and regression analyses were conducted to 
explore the relationship between cognitive test performance and functional capacity. 
 
Results:   
The mean (±SD) age of the participants was 79.9 (±8.1) years with 52.5% (n=21) 
being female. A low correlation was found between EFPT total scores and MoCA 
total scores (r= -0.22, p<0.19). A moderate correlation was found between EFPT 
total scores and ACE-III total scores (r= -0.41, p<0.01). The visuospatial domain of 
the ACE-III was significantly correlated with EFPT total score (r= -0.54, p< 0.01) 
and all four subscales of cooking oatmeal (r= -0.53, p<0.01), telephone usage (r= -
0.61, p<0.01), medication management (r= -0.50, p<0.01) and bill payment (r= -
0.52, p<0.01). In multivariable regression analysis, gender (beta=-0.39, p<0.02) and 
ACE-III total scores (beta=-0.55, p<0.01) were independently associated with EFPT 
scores. 
 
Conclusion:  
Results demonstrated low-moderate relationships between performance on the 
MoCA/ ACE-III cognitive screening tests and IADL function as measured by the 
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EFPT. It is evident that performance on cognitive screening tests alone does not 
provide the clinician with a definitive evaluation of the functional abilities of older 
adults with MCI in the acute hospital setting.  
 
Implications of Findings 
This research provides the clinician with a better understanding of the relationship 
between performance on cognitive screening tests and functional abilities in older 
adults with MCI in the acute hospital setting. It highlights the importance of 
examining cognitive subdomains of screening tests rather than just the overall score. 
It also supports the value of functional assessment for individuals with MCI. This 
study demonstrated that the ACE-III was more strongly related to IADL function 
than the MoCA and this indicates that the ACE-III should be used when assessing 
individuals with MCI. 
 
 
 
 
 
 
  
 
 
   iv 
 
ACKNOWLEGEMENTS 
 
I would sincerely like to thank Dr Helen French and Dr Tadhg Stapleton for their 
encouragement, guidance and support throughout the research process. I would also 
like to thank the lectures in the RCSI for all of their help during the past two years. 
 
I would like to thank Prof Joseph Duggan for supporting this project and a special 
word of thanks to the patients in the Mater Misericordiae University Hospital who 
made this study possible.  
 
I would especially like to acknowledge the time and effort from my Occupational 
Therapy colleagues and my Occupational Therapy Manager in the Mater 
Misericordiae University Hospital. Thank you. 
 
Finally, I would like to thank my family and friends who have always encouraged 
and supported me. Catherine, Michael, Brian and Bernard –thank you for your great 
advice, support, proof-reading and editing skills. 
 
 
 
   v 
 
TABLE OF CONTENTS  
 
SUMMARY…………………………………………………………………………..i 
ACKNOWLEGEMENTS………………………………………………………….iv 
TABLE OF CONTENTS…………………………………………………………...v 
LIST OF TABLES………………………………………………………………….ix 
LIST OF FIGURES…………………………………………………………………x 
LIST OF APPENDICES…………………………………………………………...xi 
LIST OF ABBREVIATIONS……………………………………………………..xii 
INTRODUCTION…………………………………………………………………..1 
 
CHAPTER 1 LITERATURE REVIEW……………………………………….3 
1.1 Mild Cognitive Impairment ........................................................................... 3 
1.1.1 Definition and Overview ........................................................................ 3 
1.1.2 Diagnostic Criteria ................................................................................. 4 
1.2 Cognitive Assessment in MCI………………………… ............................... 4                                            
1.3 Functional Assessment in MCI ..................................................................... 6 
1.4 The Relationship Between Cognition and Function ...................................... 9 
1.4.1 Global Cognitive Screens and Functional Status ................................... 9 
1.4.2 Cognitive Subdomains and Functional Status...................................... 11 
1.5 Conclusion ................................................................................................... 13 
   vi 
 
CHAPTER 2 METHODOLOGY……………………………………………..15 
2.1  Aim and Objectives ..................................................................................... 15 
2.2 Hypothesis ................................................................................................... 15 
2.3  Study Design ............................................................................................... 16 
2.4  Subjects ....................................................................................................... 16 
2.4.1 Sample Selection........................................................................................ 16 
2.4.2 Inclusion and Exclusion Criteria................................................................ 16 
2.4.3 Sample Size................................................................................................ 17 
2.5  Ethical Considerations ................................................................................. 18 
2.6  Procedure ..................................................................................................... 19 
2.6.1 Informed Consent ...................................................................................... 19 
2.6.2 Pilot Study.................................................................................................. 19 
2.6.3 Assessment Process ................................................................................... 20 
2.6.4 Description of Service ............................................................................... 21 
2.7  Clinical Assessment Tools .......................................................................... 21 
2.7.1 The Executive Function Performance Test (EFPT) ............................. 21 
2.7.2 The Montreal Cognitive Assessment (MoCA) .................................... 22 
2.7.3 The Addenbrooke’s Cognitive Examination (ACE-III) ....................... 23 
2.8  Statistical Methods ...................................................................................... 23 
 
 
   vii 
 
CHAPTER 3      RESULTS………...………………………………………..........25 
3.1 Introduction ................................................................................................. 25 
3.2 Participant Flow .......................................................................................... 25 
3.3 Demographic Characteristics of Participants .............................................. 26 
3.4 Clinical Characteristics of Participants ....................................................... 28 
3.5      Correlations between EFPT and cognitive screening tests ......................... 32 
3.6     Correlations between EFPT and cognitive subdomains ............................... 33 
3.7     Univariable regression analysis .................................................................... 35 
3.8     Multivariable regression analysis………………………………………… 35 
3.9 Summary of results ...................................................................................... 35 
 
CHAPTER 4 DISUCSSION…………………………………………………..37 
4.1 Introduction ................................................................................................. 37 
4.2 Review of Participants’ Demographic Characteristics ................................ 37 
4.3 Review of Participants’ Clinical Characteristics ......................................... 38 
     4.4     IADL Deficits in MCI……………………………………………………..38 
4.5      Relationship between IADL Function and Overall Performance on               
Cognitive Screening Tests ...................................................................................... 39 
4.6 Relationship between IADL Function and Individual Cognitive Domains 42 
     4.7     Additional Factors Associated with IADL Function……………………...47 
4.8 Clinical Relevance ....................................................................................... 47 
   viii 
 
4.9 Limitations of the Study .............................................................................. 50 
4.10 Recommendations for Future Research ...................................................... 52 
CONCLUSION………………………………………………………………….....53 
REFERENCES…………………………………………………………………….54 
 
   ix 
 
LIST OF TABLES 
 Page No. 
Table 3.1 Demographic characteristics of participants    27
    
Table 3.2 Clinical characteristics of participants    29 
Table 3.3 Correlations between EFPT and cognitive screening tests  30 
Table 3.4 Correlations between EFPT and cognitive subdomains of  33 
the MoCA and ACE-III  
Table 3.5 Univariable linear regression analysis    34 
Table 3.6 Multivariable linear regression analysis    35 
 
 
 
 
 
 
 
 
 
 
 
 
 
   x 
 
LIST OF FIGURES 
 Page No. 
Figure 3.1 Participant fow through the study     26 
Figure 3.2 Scatter plot diagram of the relationship between EFPT  31 
total scores and MoCA total scores 
Figure 3.3 Scatter plot diagram of the relationship between EFPT  31 
total scores and ACE-III total scores 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   xi 
 
LIST OF APPENDICES 
 Page No. 
Appendix 1  Ethics Application Form     65 
Appendix 2  MMUH Ethical Approval Letter    94 
Appendix 3  RCSI Ethical Approval Letter    95 
Appendix 4  Participant Information Leaflet    96 
Appendix 5  Participant Consent Form     98 
Appendix 6  Letter of Notification to Consultant             100 
Appendix 7  Data Collection Form               101 
Appendix 8  Montreal Cognitive Assessment             104 
Appendix 9  Addenbrooke’s Cognitive Examination            105 
Appendix 10  Executive Function Performance Test            111 
 
 
 
 
 
 
 
 
 
 
 
   xii 
 
LIST OF ABBREVIATIONS 
 
ACE-III  Addenbrooke’s Cognitive Examination-III 
ACE-R  Addenbrooke’s Cognitive Examination-Revised 
AD   Alzheimer’s Disease 
ADL   Activities of Daily Living 
BADL   Basic Activities of Daily Living 
CI   Confidence Interval 
DADL   Domestic Activities of Daily Living 
DSM-5 Diagnostic and Statistical Manual of Mental Disorders, 5
th
 
Edition 
EFPT   Executive Functional Performance Test 
IADL   Instrumental Activities of Daily Living 
IQR   Interquartile Range 
MCI   Mild Cognitive Impairment 
MDT   Multidisciplinary Team  
MMSE  Mini-Mental State Examination 
MMUH  Mater Misericordiae University Hospital 
MoCA   Montreal Cognitive Assessment 
OT    Occupational Therapy 
PADL   Personal Activities of Daily Living 
RCSI   Royal College of Surgeons in Ireland 
SD   Standard Deviation 
SPSS   Statistical Package for the Social Sciences 
STROBE Strengthening the Reporting of Observational Studies in 
Epidemiology
  1   
 
INTRODUCTION 
Mild cognitive impairment (MCI) is a condition that results in subtle decline in 
cognitive abilities (Lin et al., 2012). The cognitive deficits in MCI are not confined 
to memory and may include impairments in multiple cognitive domains such as 
attention, executive function and visuospatial abilities (Albert et al., 2011). In 
addition to cognitive deterioration, individuals with this condition may also 
experience difficulties in completing instrumental activities of daily living (IADL) 
such as meal preparation, medication management and use of everyday technology 
(Aretouli and Brandt, 2010; Marshall et al., 2011; Reppermund et al., 2011; 
Vermeersch et al., 2015). 
 
Occupational therapists (OTs) play an important role in assessing individuals with 
MCI in terms of functional abilities and evaluating the impact of cognitive 
impairment on daily living tasks (Gold, 2012). OTs working in the acute care setting 
are routinely asked to make judgements regarding the ability of patients with MCI to 
complete various IADL tasks in order to facilitate their safe discharge from hospital. 
Functional assessments and psychometric tests are utilised by OTs to determine 
individuals’ abilities to complete various activities of daily living (ADLs) and to 
make judgements about their capacity to live independently (Marcotte and Grant, 
2009; Vermeersch et al., 2015).  
 
Cognitive screening tools such as the Montreal Cognitive Assessment (MoCA) and 
the Addenbrooke’s Cognitive Examination (ACE-III) are regularly administered by 
acute hospital OTs to assist in predicting the functional capacities of this client 
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group. However anecdotal findings from clinical practice show that performance on 
cognitive screening tools is not always consistent with functional task performance.  
 
The relationship between cognitive and functional domains has been investigated in 
a number of studies involving MCI and dementia populations (Baum et al., 1995; De 
Paula and Malloy-Diniz, 2013; Farias et al., 2003; Perry and Hodges, 2000) which 
have predominately yielded modest results, with cognitive test performance 
generally accounting for moderate amounts of variance in functional abilities. The 
majority of this research has been undertaken in community-dwelling and 
residential-care settings with no evidence pertaining to hospitalised older adults 
existing. Previous research investigating the relationship between cognition and 
function has used a wide variety of neuropsychological tests however there is a 
paucity of research involving the MoCA and ACE-III tools which are common to 
OT practice in the acute setting. Furthermore, the majority of previous research 
studies used informant-based or self-report functional assessments which may be 
prone to bias.  
 
The current study aims to extend the work of previous research pertaining to the 
relationship between cognitive and functional domains in MCI. To address the 
limitations of previous studies, the current study will employ a performance-based 
measure of functional status (Executive Function Performance Test, EFPT) that is 
weighted towards cognitively-orientated IADLs. Cognitive screening tools that are 
routinely administered in OT practice within the acute care setting will be used to 
assess participants’ cognitive status. 
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CHAPTER 1 LITERATURE REVIEW 
 
1.1 Mild Cognitive Impairment 
 
1.1.1 Definition and Overview 
Mild cognitive impairment (MCI) has been defined as a transitional state between 
the cognitive changes of normal ageing and the more serious decline of early 
dementia (Petersen, 2004; Peterson, 2011; Winblad et al., 2004). Approximately 
22% of older adults aged 71 years and above have diagnosed MCI with an increasing 
prevalence evident with advancing age (Brookmeyer et al., 2011). MCI contains 
several subtypes that assume differences in clinical presentation and progression 
(Yen-Chi et al., 2011). Clinical subtypes include amnestic-MCI single domain, 
amnestic-MCI multiple domains, non-amnestic-MCI single domain, and non-
amnestic MCI multiple domains (Faucounau et al., 2010). Individuals with MCI 
exhibit cognitive and functional impairments similar to those that characterise 
Alzheimer’s disease (AD), although of a milder and usually more focal nature 
(Okonkwo et al., 2008). MCI populations are at high risk of progressing to dementia 
and losing functional independence (Reppermund et al., 2011). For those with MCI, 
the progression to AD or other dementias continues in roughly 20-30% of 
individuals within three years with a greater transition rate in those with amnestic-
MCI single domain or amnestic-MCI multiple domains subtypes (Valcour et al., 
2000).  
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1.1.2 Diagnostic Criteria 
The diagnostic criteria for MCI have been controversial, particularly regarding 
whether functional deficits should be considered a core feature of the condition 
(Giovannetti et al., 2008). A number of studies have concluded that subtle 
difficulties on complex daily tasks are common in MCI (Farias et al., 2003; Peterson, 
2004; Winblad et al., 2004). Clear diagnostic criteria for MCI has recently been 
established by the International Working Group on MCI (Winblad et al., 2004) and 
includes the following: a) presence of subjective cognitive complaints by either the 
participant or informant b) presence of cognitive impairment in one domain or more 
based on a threshold equivalent to 1.5 standard deviations or more below published 
normative data, c) normal or minimally impaired in functional abilities and d) no 
dementia according to the Diagnostic and Statistical Manual of Mental Disorders 
(DSM) criteria. 
 
1.2 Cognitive Assessment in MCI 
OT theory and research support the principle that cognition is essential to the 
performance of everyday tasks (Toglia and Kirk, 2000). Cognition refers to the 
information-processing functions carried out by the brain which include the skills of 
attention, memory, executive function, comprehension and formation of speech, 
calculation ability, visual perception and praxis skills (American Occupational 
Therapy Association, 2013). MCI causes a decline in cognitive abilities including 
memory, executive functioning, abstract thinking and social cognition (Yanhong et 
al., 2013). The consequences of cognitive impairment can significantly impact the 
way in which an individual functions in everyday life (Joliffe et al., 2015). 
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Controversy exists as to how MCI can be best assessed as there is insufficient 
evidence to recommend specific cognitive tests and cut-off scores (Winblad et al., 
2004). OTs commonly use cognitive tests to assist in making decisions about a 
person’s ability to perform day-to-day tasks (Vermeersch et al., 2015). Cognitive 
abilities are assessed under the assumption that they are the underlying foundation 
skills necessary for successful daily task performance (Joliffe et al., 2015). 
Therapists often make predictions about an individual’s functional ability based on 
performance on cognitive screening assessments (Katz et al., 2002). Previous 
research provides a strong foundation of evidence to suggest that cognitive status 
shares a strong association with functional status (Brown et al., 2013). However, 
anecdotal findings from OT clinical practice demonstrate that performance on 
cognitive screening tests is not always consistent with performance of everyday 
functional tasks amongst individuals with cognitive impairment. The ability of 
cognitive tests to predict everyday functional abilities is a strong research interest 
and clinical necessity (Yantz et al., 2010).  
 
The process of selecting the most appropriate cognitive assessments to use with 
individuals with MCI is an important consideration (Joliffe et al., 2015). Cognitive 
screening tools such as the MoCA and the ACE-III are regularly administered by 
acute hospital OTs to assist in predicting the functional capacities of individuals with 
MCI. However, few studies have investigated the association between cognitive 
skills and functional performance using the MoCA and ACE-III. Assessment of 
cognitive abilities is common practice in the acute hospital context (Joliffe et al., 
2015) however there is a significant lack of research examining the link with 
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cognitive and functional domains amongst individuals with MCI within this clinical 
setting. 
 
1.3 Functional Assessment in MCI 
There is significant research to show that individuals with MCI experience 
difficulties in their ability to complete IADL tasks (Belchior et al., 2015). 
Giovannetti et al. (2008) evaluated the degree and pattern of functional deficits in 
MCI via direct observation of everyday task performance. Individuals with MCI 
(n=25), mild AD (n=25) and healthy controls (n=18) completed the Naturalistic 
Action Test (NAT). The NAT involves three everyday tasks of increasing 
complexity including preparation of toast and coffee, gift-wrapping a present and 
packing a child’s lunchbox and schoolbag. Results showed that individuals with 
MCI demonstrated subtle deficits due to the inefficient and imprecise execution of 
task steps. The authors suggested that the functional deficits in MCI differ in both 
degree and type from the functional deficits in dementia i.e. individuals with MCI 
have more difficulty performing steps of tasks accurately (commission errors) 
however individuals with AD show errors in commission but also in omission. This 
is in agreement with findings from research by Ciro et al. (2015) which suggested 
that IADL deficits in MCI were related to adequacy and quality of task performance 
rather than safety and independence. 
 
A systematic review by Jekel et al. (2015) summarised research results regarding the 
performance of individuals with MCI in specific IADL tasks compared with 
individuals who are cognitively normal and/or individuals with dementia. This 
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systematic review included 37 studies. Results showed that IADLs with higher 
neuropsychological demand, such as financial capacity, shopping, keeping 
appointments, driving and everyday technology use were most severely affected in 
MCI. There was no consensus regarding which IADL domains are typically impaired 
in MCI, however activities that require higher cognitive processes appear to be 
affected.  
 
Burton et al. (2009) found that adults with multiple-domain MCI demonstrated 
poorer IADL function than older adults with no cognitive impairment on the 
Everyday Problems Test and the Scale of Independent Behaviour-Revised test. They 
also stated that IADL deficits in MCI may be too subtle to be detected by certain 
functional assessment measures. Similarly, Gold (2012) and Aretouli and Brandt 
(2010) suggested that multi-domain MCI was associated with greater functional 
impairment than single-domain MCI. 
 
Griffith et al. (2003) examined everyday functioning in MCI using a standardised 
measure of financial capacity. Findings revealed that specific domains of 
occupational performance were more impaired than others e.g. cheque book 
management versus transactions. They also found that MCI and control participants 
differed only on the more complex financial tasks. Interestingly, MCI participants 
did not differ from controls in their financial knowledge however they were not 
always capable of applying this knowledge to the task. Furthermore, Rodakowski et 
al. (2014) found that two functional tasks of shopping and cheque book balancing, 
measured by the observation-based Performance Assessment of Self-Care Skills, 
demonstrated increased effort for individuals with MCI. 
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Functional assessment can assist in judging the clinical significance of impairment in 
certain neuropsychological tests or domains amongst individuals with MCI 
(Reppermund et al., 2011). Several options exist for assessing IADL in MCI 
including informant-report, self-report or performance-based measures. Different 
methods of assessing functional abilities provide varying estimates of IADL 
independence and each approach has it’s advantages and disadvantages (Burton et 
al., 2009).  
 
The majority of studies investigating IADL function in MCI have used self-report or 
informant-report instruments to assess occupational performance. Informant and 
self-report assessments show monetary and temporal efficiency in assessing a wide 
range of activities in a short time period (Gold, 2012). However they can have 
potential limitations including the risk of reporter bias. Furthermore reporters may 
not always be able to distinguish different causes of disability and subsequently 
under or overestimate an individual’s functional abilities (Reppermaud, 2011). 
Performance-based measures typically involve observing an individual enact an 
IADL such as meal preparation or medication management. Performance-based 
assessments have been criticised for removing the individual’s chosen routines and 
environmental cues that typically facilitate IADL performance (Gold, 2012). 
However, there is much evidence to show that they may be more valid as there is 
direct observation of how an individual performs a task with precise definition of 
IADL deficits (Ciro et al., 2015). They also have the advantage of objectively 
scoring individuals on their ability to perform everyday activities rather than relying 
on subjective self-rating or second-party judgement (Reppermund et al., 2011).  
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A systematic review of 37 studies by Jekel et al. (2015) recommended use of IADL 
assessment tools specifically designed and validated for patients with MCI. The 
authors recommend that use of performance-based assessments should be intensified 
as they allow a valid and reliable assessment of subtle IADL deficits in MCI. 
Furthermore, a study by Goldberg et al. (2010) demonstrated that performance-based 
measures of everyday function are sensitive tools in the evaluation of individuals 
with MCI. Many performance-based functional assessments have been developed in 
recent years including the EFPT which is a standardised performance-based 
assessment of functional abilities to complete functional tasks of cooking, telephone 
usage, medication management and bill payment. 
 
1.4 The Relationship between Cognition and Function 
1.4.1 Global Cognitive Screening Tests and Functional Status 
The relationship between cognitive and functional domains has been investigated in 
a number of studies (Baum et al., 1995; De Paula and Malloy-Diniz, 2013; Farias et 
al., 2003; Perry and Hodges, 2000) which have predominately yielded modest results 
with neuropsychological performance generally accounting for moderate amounts of 
variance in function. Previous research demonstrates mixed results regarding the 
nature of the relationship between cognitive and functional domains in MCI. 
Although cognition is a strong predictor of everyday functioning, there is still no 
consensus on the relationship between cognition and ADLs (Vermeersch et al., 
2013).  
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Vermeersch et al. (2015) completed an exploratory study to investigate the 
relationship between functional decline and cognitive decline in 45 persons with 
MCI, 48 persons with AD and 50 cognitively healthy controls. Cognitive function 
was measured using the Mini Mental State Examination (MMSE) and the Cambridge 
Cognition Examination (CAMCOG). Functional ability was evaluated using three 
IADL tasks from the Advanced Activities of Daily Living Tool, namely use of 
everyday technology, driving a vehicle and performing complex economic activities. 
For the sample as a whole, moderate to strong negative correlations (ranging from r= 
-0.276 to -0.613) were found between the cognitive measures and all of the IADL 
domains. However, within each subgroup, only two significant correlations were 
found. For the MCI group, no significant correlations were found between cognitive 
decline and functional decline. This may be due to a loss of statistical power given 
reduced range and variation of cognitive and functional scores within the difference 
population groups. 
 
Joliffe et al. (2015) examined if clients’ performances on the Rowland Universal 
Dementia Assessment Scale (RUDAS) were associated with their functional 
performance as measured by the Functional Independence Measure (FIM) (n=30). 
They found that the six RUDAS scale items were significantly associated with FIM 
total score (r²= 0.230, p<0.05), FIM cognition subscale (r²= 0.35, p<0.05) and FIM 
physical subscale (r²=0.24; p<0.05). They concluded that the RUDAS cognitive 
screen is associated with the functional abilities of older adults with dementia. 
 
Reppermund et al. (2011) examined the differences in IADL between individuals 
with MCI and cognitively normal elderly people and also examined the relationships 
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of IADL with cognitive functions.  Seven hundred and sixty-two community-
dwelling older adults were assessed with a comprehensive neuropsychological test 
battery and MMSE and the informant-completed Bayer-Activities of Daily Living 
Scale. Small but statistically significant negative correlations were found between 
IADL scores and each of the five cognitive domains of memory (r=-0.12, p<0.01), 
attention/ processing speed (r=-0.16, p<0.01), visuospatial (r=-0.09, p<0.01), 
language (r=-0.14, p<0.01) and executive functions (r=-0.11, p<0.01). Furthermore, 
results showed that people with MCI have more difficulties in IADL, especially 
those that require a high demand on cognitive capacities.  
 
Similarly, a systematic review by Royall et al. (2007) identified and compared 68 
papers that had reported regression analyses of cognitive measures with functional 
outcomes. In total, 156 individual regression models comprising 812 unique 
associations between a cognitive measure and a functional outcome were identified. 
On average it was found that cognition explained 21% of variance in functional 
outcomes. Overall, the association between cognitive measures and functional 
outcomes was modest at best. 
 
1.4.2 Individual Cognitive Subdomains and Functional Status 
Previous research has shown that certain cognitive domains such as verbal learning, 
memory and executive function may be more strongly related to functional status 
than others (Farias et al., 2003; Okonkwo et al., 2006). Goldberg et al. (2010) found 
a strong and significant relationship between cognitive domains of processing speed, 
episodic memory and semantic processing and performance-based functional 
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assessment score. Reppermund et al. (2011) found associations between deficits in 
IADL measures and executive function with strong links between memory and 
psychomotor speed. Lorch and Earland (2015) stated that the primary concerns 
facing these individuals with MCI are deficits with attention, memory and aspects of 
executive functioning, as they related to and impact occupational participation and 
functioning. 
 
Royall et al. (2007) found that executive and general cognitive measures explained 
significantly more variance in functional outcomes than memory, attention or verbal 
measures, with simple cognitive screening tests such as the MMSE more strongly 
associated with functional outcomes than formal neuropsychiatric measures. The 
authors concluded that executive and general cognitive measures explained 
significantly more variance in functional outcomes. 
 
In addition, Aretouli and Brandt (2010) investigated the contribution of three 
domains of executive function to everyday functioning in individuals with MCI 
(n=124) and cognitively normal elderly participants (n=68). Three domains of 
executive function included working memory, judgement and planning/problem-
solving. Results showed that functional abilities are compromised in all MCI 
subtypes. Contrary to expectations, only one executive function component, working 
memory contributed significantly to functional status after controlling for 
demographic, health-related and other cognitive factors.  
 
Marshall et al. (2011) investigated the relationship between executive function and 
IADL in a large cohort of cognitively normal controls (n=228), mild cognitive 
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impairment (n=387) and mild AD participants (n=178). Results demonstrated a 
significant relationship between executive function deficits and IADL impairment 
across all subject groups. The relationship was evident even after accounting for 
degree of memory deficit across the continuum of cognitive impairment and 
dementia. Furthermore, Bell-McGinty et al. (2002) reported that executive function 
accounted for 54% of the variability in a performance-based measure of IADL in a 
sample of older adults.  
 
Schmitter-Edgecombe et al. (2009) evaluated multiple memory processes and 
explored their contributions to functional deficits in individuals with amnestic and 
non-amnestic subtypes of MCI. Findings demonstrated that impairments in memory 
beyond the traditionally assessed content memory were present in individuals with 
amnestic and non-amnestic MCI. Furthermore, the results showed that these non-
content memory processes, which have been linked with executive functioning, play 
a role in supporting IADL performance. Although there have been a number of 
studies exploring the relationship between cognitive test performance and IADL 
function, there has been no research using MoCA or ACE-III. Most IADL 
instruments were report-based and included a variety of rather simple activities that 
did not require a high degree of cognitive processing. 
 
1.5 Conclusion 
MCI can result in deficits of cognitive and functional abilities. Psychometric tests 
and functional assessments are regularly used with MCI patients in the acute hospital 
setting to assist in making decisions regarding their capacity to live independently 
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and complete various ADLs. However findings from clinical practice and the 
literature show mixed results regarding the relationship between cognitive test 
performance and functional status in MCI. 
 
Previous research in this area has many limitations including use of informant or 
self-report functional measures; use of wide variety of neuropsychological batteries 
which makes comparison between studies difficult; and lack of research within the 
acute hospital setting. The current study aims to extend the work of previous 
research pertaining to the relationship between cognitive and functional domains in 
MCI. To address the limitations of previous studies, the current study will employ a 
performance-based measure of functional status (EFPT) which is weighted towards 
cognitively-demanding IADLs. Cognitive screening tools that are routinely 
administered in OT practice within the acute care setting will be used to assess 
participants’ cognitive status. 
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CHAPTER 2 METHODOLOGY  
 
2.1  Aim and Objectives 
The aim of this research was to explore the relationship between cognitive test 
performance and IADL function in older adults with MCI in the acute hospital 
setting. 
 
The objectives were: 
1. To determine which global cognitive screening tool (MoCA or ACE-III) is 
most strongly related to IADL function in older adults with MCI. 
2. To examine the relationship between individual cognitive subdomains of the 
MoCA/ ACE-III tests and IADL function in older adults with MCI. 
3. To examine the influence of various cognitive and demographic variables on 
IADL function in older adults with MCI. 
 
2.2 Hypothesis  
It was hypothesised that there would be a moderate negative correlation between 
cognitive test performance and IADL function in older adults with MCI in the acute 
hospital setting. 
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2.3  Study Design 
This study employed a cross-sectional design to investigate the relationship between 
cognitive test performance and IADL function in older adults with MCI in the acute 
hospital setting. The Strengthening the Reporting of Observational Studies in 
Epidemiology (STROBE) statement guidelines were reviewed during development 
of the research design to ensure methodological validity (Von Elm et al., 2008). 
 
2.4  Subjects 
2.4.1 Sample Selection 
Participants were recruited from the Care of the Older Person and General Medical 
inpatient services within the Mater Misericordiae University Hospital (MMUH). A 
clinical sample of convenience was used. Recruitment took place over a five-month 
period between October 2015 and February 2016.  
 
2.4.2 Inclusion and Exclusion Criteria 
Inclusion Criteria: 
 Diagnosis of MCI according to published criteria by Peterson (2004) and 
Winblad et al. (2004) with a score of 18-25/30 on MoCA. 
 Aged 65 years or older. 
 Referred to OT.  
 Medically stable. 
 Willing and able to provide informed consent. 
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 Able to comprehend, read and write English. 
 Living at home at baseline and participating in at least one IADL. 
 Able to engage in functional assessment at time of recruitment with 
maximum physical support level of assistance of one. 
 
Exclusion Criteria:  
 Presence of delirium according to Diagnostic and Statistical Manual of 
Mental Disorders (DSM-5) criteria (American Psychiatric Association, 
2013). 
 Diagnosis of dementia according to DSM-5 criteria (American Psychiatric 
Association, 2013). 
 Communicative or sensory impairment that could significantly interfere with 
ability to engage in assessments. 
 Neurological disorder that could affect cognition e.g. cerebrovascular 
accident, traumatic brain injury, multiple sclerosis, Parkinson’s disease.  
 Major psychiatric disorder affecting cognition. 
 History of substance (drug or alcohol) abuse. 
 Developmental disability. 
 
2.4.3 Sample Size 
The sample size calculation was derived from previously published data for studies 
that produced statistically significant results pertaining to the psychometric 
properties of the EFPT (Baum et al., 2008; Cederfeldt et al., 2011; Cederfeldt et al., 
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2015). The mean number of participants used in these studies was calculated at 
n=37.66. The current study had a sample size of n=40. In addition, Conroy (2009) 
recommended a sample size of 40 to detect a correlation of 0.55 or greater for a 
study powered at 95%. 
 
2.5  Ethical Considerations 
Ethical approval was sought from the MMUH and RCSI Research Ethics 
Committees (Appendix 1).  Recruitment commenced following written approval 
from both ethics committees (Appendix 2 and Appendix 3). All data were collected 
in accordance with the Declaration of Helsinki (World Medical Association, 2013) 
and stored under the Data Protection Act (2003) and the Data Protection Guidelines 
on Research in the Health Sector Act (2007). To ensure confidentiality, each 
participant was given a unique code. This was then used as the only identifiable 
marker on all hard copy record sheets and electronic records. The primary researcher 
had access to a separate Excel file, which linked the codes to the participants. 
Electronic records were stored on a secure encrypted USB flash drive and a 
password-protected desktop computer in the MMUH. Paper records and the 
encrypted USB flash drive were stored in a locked filing cabinet in the OT 
department at the MMUH. Data will be stored securely for five years and thereafter 
destroyed in accordance with the ethics committee policy. 
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2.6  Procedure 
2.6.1 Informed Consent 
The selection criteria were applied to all patients referred to OT from the Care of the 
Older Person and General Medical inpatient services within the MMUH. Eligible 
participants were invited to participate in the study by a gatekeeper who was an OT 
colleague working in the Care of the Older Person or General Medical service. The 
gatekeeper provided eligible participants with a participant information leaflet 
(Appendix 4) outlining the purpose of the study. These potential participants were 
given a 24-hour period of time to allow comprehension of the information provided.  
Potential participants were then approached by the primary researcher who provided 
additional study details and answered specific questions as required. If participants 
agreed to take part in the study, they were asked to sign a participant consent form 
(Appendix 5). Once informed consent was gained, the primary researcher began data 
collection. Participants were made aware of their ethical right to withdraw from the 
study at any time without any consequences or influence on further treatment. A 
letter of notification was sent to each participant’s consultant (Appendix 6) to inform 
them of the patient’s decision to partake in the study. 
 
2.6.2 Pilot Study  
A pilot study was completed prior to the main study. Two participants were recruited 
and assessed by the primary researcher for the purpose of the pilot study. This 
allowed the primary researcher to estimate the amount of time required to collect 
data, to test the clinical assessment tools, to trial the data collection form and to 
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identify unforeseen limitations to the research design. No changes to the study 
protocol were made following the pilot study and therefore this data were included in 
the final statistical analysis. 
 
2.6.3 Assessment Process 
Demographic and baseline clinical information were obtained from the participant’s 
medical chart by the primary researcher. This included age, gender, education level, 
presenting complaint, number of co-morbidities, number of medications and social 
history. This information was recorded in the data collection form (Appendix 7). The 
primary researcher administered all of the clinical assessments to ensure the 
assessment process was standardised. The clinical assessment measures used in the 
study consisted of the MoCA (Appendix 8), the ACE-III (Appendix 9) and the EFPT 
(Appendix 10). Training in administering and scoring the assessments was not 
required as the primary researcher was experienced in using the tools in routine 
clinical practice. In some cases, a cognitive screen (MoCA or ACE-III) had already 
been conducted with participants by their treating OT prior to their enrollment in the 
study. In such cases, the primary researcher administered an alternative version of 
the cognitive screening test with participants during data collection to eliminate 
possible learning effects. 
 
The clinical assessment tools were administered over two sessions to minimise the 
effects of participant fatigue. The assessment process was standardised and all 
clinical evaluations were administered according to standardised test instructions. 
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The cognitive screening tests (MoCA and ACE-III) were administered in the first 
session which took place in a quiet environment on the ward and lasted 
approximately 20-30 minutes. The second session was completed the following day 
and involved administration of the functional assessment (EFPT). The second 
session took place in the OT department and lasted approximately 30-45 minutes. 
 
2.6.4  Description of Service 
Participants received routine OT input in the acute hospital setting during the course 
of the study consisting of comprehensive assessment, patient-centered goal-setting, 
intervention and discharge planning. This was in the context of a multidisciplinary 
team service consisting of input from the medical team, nursing staff and health and 
social care professionals as appropriate.  
 
2.7  Clinical Assessment Tools 
2.7.1 The Executive Function Performance Test (EFPT) 
The Executive Function Performance Test (EFPT; Baum et al., 2003) is a 
performance-based standardised assessment of functional capacity. It can help OTs 
to determine the level of support needed by people with cognitive impairments to 
complete IADLs (Baum et al., 2008). The tool serves three main purposes: a) to 
determine which executive functions are impaired, b) to determine an individual’s 
capacity for independent functioning and c) to determine the amount of assistance 
required for task completion (Baum et al., 2007). It is composed of four real-world 
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tasks that are necessary to support independent living namely cooking, telephone 
usage, medication management and bill payment (Gillen, 2009). It takes 
approximately 30-45 minutes to administer. The tool uses a structured cueing and 
scoring system to assess cognitive skills and functional abilities. The total score 
range is 0-100 with higher scores indicating more severe deficits. The EFPT has 
been validated in studies with various populations including people with dementia 
(Baum and Edwards, 1993), multiple sclerosis (Goverover et al., 2009), stroke 
(Baum et al., 2008; Cederfeldt et al., 2011; Cederfeldt et al., 2015) and schizophrenia 
(Katz et al., 2007). It has excellent inter-rater reliability (ICC=0.91) and internal 
consistency (α=0.94) (Baum et al., 2008). 
 
2.7.2 The Montreal Cognitive Assessment (MoCA) 
The MoCA is a brief cognitive screening test that was developed by Nasreddine et 
al. (2005) to assist health care professionals in the detection of MCI. This tool is 
widely used in international clinical practice to evaluate cognitive skills (Julayanont 
et al., 2012). It requires approximately 10 minutes to administer and one minute to 
score. The total possible score is 30 points with a score of 26 or above considered 
normal (Nasreddine et al., 2005).  The tool assesses multiple cognitive domains 
including attention, concentration, executive functions, memory, language, 
visuospatial skills, conceptual thinking, calculation and orientation (Trzepacz et al., 
2015). It has high sensitivity (average 86%, range 77%-96%) and specificity 
(average 88%, range 50%-98%) for detecting MCI and AD (Julayanont et al., 2012). 
It has excellent test-retest reliability (r=0.92) and good internal consistency (=0.83) 
within a MCI population (Nasreddine et al., 2005). 
  23   
 
2.7.3 The Addenbrooke’s Cognitive Examination (ACE-III) 
The ACE-III was developed by Hsieh et al. (2013) to provide a brief cognitive test 
sensitive to the early stages of dementia. It is an updated version of the previous 
Addenbrooke’s Cognitive Examination-Revised (ACE-R) which is one of the most 
widely used cognitive assessments in routine clinical practice with geriatric 
populations (Larner, 2007; Mioshi et al., 2006). The tool takes approximately 15 
minutes to administer and five minutes to score. The total score is 100 and the cut-
off for dementia is 82-88/100 (Crawford et al., 2012). It assesses five cognitive 
domains of attention, memory, verbal fluency, language and visuospatial abilities. 
The ACE-III correlates significantly with the ACE-R (r=0.99), demonstrating similar 
levels of sensitivity (93%-100%) and specificity (96%-100%) for detecting dementia 
(Hsieh et al., 2013). The ACE-III has excellent internal reliability (=0.88-0.93) and 
inter-rater reliability (ICC=0.98) (Hseih et al., 2013; Matias-Guiu, 2015).  
 
2.8  Statistical Methods 
The Statistical Package for the Social Sciences (SPSS) Version 22.0 for Windows 
(IBM Corp., 2013) was used to analyse the data. Data were examined for normality 
using skewness and kurtosis values, normal probability plots, histograms and the 
Shapiro-Wilk’s test. Descriptive statistics were used to describe the demographic and 
clinical characteristics of the group, using parametric and non-parametric methods as 
appropriate.  
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Spearman’s rank-order correlation coefficient test for non-parametric data was used 
to examine the relationship between IADL function and cognitive test performance. 
Cohen (1988) criteria were used to determine the strength of the relationships 
between variables where 0.01-0.29 was considered a small correlation, 0.30-0.49 
was considered a moderate correlation and 0.50-1.0 was considered a large 
correlation. Spearman’s rank correlation coefficient was also used to examine the 
relationship between IADL function and individual cognitive subdomains of the 
MoCA and ACE-III tests.  
 
Univariable linear regression analysis was carried out to examine the influence of 
various demographic and cognitive variables on IADL function. Variables that were 
significant at the 0.15 level in the univariable regression analysis were entered into a 
multivariable linear regression model. McCowan et al. (2011) stated that variables 
must have a p-value of ≤ 0.15 in univariable analysis to be entered into a 
multivariable model. The multivariable regression model was used to examine 
whether any of the cognitive and demographic factors were independently associated 
with IADL function. All tests (with the exception of the univariable analyses) were 
completed with a 0.05 level of significance. The results are presented in Chapter 
Three. 
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CHAPTER 3 RESULTS 
 
3.1 Introduction 
The aim of this research was to explore the relationship between cognitive test 
performance and IADL function in older adults with MCI in the acute hospital 
setting. 
 
The objectives were: 
1. To determine which global cognitive screening tool (MoCA or ACE-III) 
is most strongly related to IADL function in older adults with MCI. 
2. To examine the relationship between individual cognitive subdomains of 
the MoCA/ ACE-III tests and IADL function in older adults with MCI. 
3. To examine the influence of various cognitive and demographic variables 
on IADL function in older adults with MCI. 
 
3.2 Participant Flow  
Recruitment took place from October 2015 to February 2016. Fifty-three patients 
were identified by gatekeepers as eligible for inclusion in the study and provided 
with information leaflets. Forty-seven patients consented to participate in the 
research. The final study sample consisted of 40 participants. The flow of patients 
through the study is outlined in Figure 3.1. 
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Figure 3.1 Participant flow through the study 
 
3.3 Demographic Characteristics of Participants 
The mean (±SD) age of the participants was 79.9 (±8.1) years with 52.5% (n=21) 
being female. Seventy-five percent (n=30) of participants were recruited from 
general medical wards and 25% (n=10) from the care of the older person service. 
The median (IQR) number of comorbidities of the sample was 4 (2). The participants 
required a mean (±SD) of 8.4 (±3.4) medications and 85% had polypharmacy (taking 
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>4 medications). Seventy percent (n=28) of the sample lived alone. Of the 30% 
(n=12) who lived with others, 15% (n=6) lived with a spouse, 10% (n=4) lived with 
offspring and 5% (n=2) lived with a sibling.  
 
Table 3.1 Demographic characteristics of participants (n=40) 
Demographic Characteristics  
Age (years)  Mean (±SD) 79.9 (±8.1) years 
 
 
Gender/ Sex 
 
Female 
Male 
 
% (n=number of participants) 
52.5% (n=21) 
47.5% (n=19) 
 
Nationality 
 
Irish 
English 
Scottish  
 
 92.5% (n=37) 
5.0% (n=2) 
2.5% (n=1) 
Presenting condition Fall/ collapse 
Respiratory condition 
Functional decline 
Cardiac condition 
Back pain 
Cancer 
Osteoarthritis 
Venous leg ulceration 
Other: GI bleed, bleeding 
permcath site 
 
 32.5% (n=13) 
22.5% (n=9) 
12.5% (n=5) 
7.5% (n=3) 
5.0% (n=2) 
5.0% (n=2) 
5.0% (n=2) 
5.0% (n=2) 
5.0% (n=2) 
Recruitment source General medicine 
Care of the older person 
 
 75.0% (n=30) 
25.0% (n=10) 
Highest education level 
attained 
 
Primary 
Secondary  
Third level 
 
 40.0% (n=16) 
52.5% (n=21) 
7.5% (n=3) 
Marital status Widowed 
Single 
Married 
Divorced/ separated 
 
 45.0% (n=18) 
30.0% (n=12) 
15.0% (n=6) 
10/0% (n=4) 
Living status Lives alone 
Lives with others 
 
 70.0% (n=28) 
30.0% (n=12) 
Self-reported cognitive 
impairment 
 
Yes 
No 
 
 95.0% (n=38) 
5.0% (n=2) 
Number of comorbidities 
 
 
 
Median (IQR) 4 (2) 
Number of medications 
 
Mean (±SD) 8.4 (±3.4)  
 
GI=gastro-intestinal; IQR = interquartile range; n= number of participants; SD = standard deviation 
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Approximately 32% (32.5%, n=13) of participants were admitted following a fall or 
collapse. Respiratory-related conditions accounted for 22.5% (n=9) of presenting 
conditions and functional decline accounted for 12.5% (n=5) of the sample. Forty 
percent (n=16) of the sample achieved primary level education, 52.5% (n=21) 
continued to secondary level and only 7.5% (n=3) progressed to third level 
education. Ninety-five percent (n=38) of participants reported subjective cognitive 
deficits. Full details regarding the demographic characteristics of participants are 
provided in Table 3.1. 
 
3.4 Clinical Characteristics of Participants  
The median (IQR) MoCA total score for the sample was 20(4) whereby the score 
range is 0-30 and higher scores indicate better cognitive performance. The median 
ACE-III total score was 70 (17) whereby the score range is 0-100 and higher scores 
indicate better cognitive functioning. The mean (±SD) EFPT total score was 23.34 
(±9.0) whereby the score range is 0-100 and lower scores are indicative of better functional 
performance. Participants had greatest difficulty with the EFPT subtask of bill 
payment with a mean (±SD) score of 8.92 (±3.0). Participants had least difficulty 
with the EFPT subtask of medication management with a mean (±SD) score of 4.18 
(±2.32). A clinical profile of participants’ cognitive and functional assessment scores 
is presented in Table 3.2.                           
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Table 3.2 Clinical characteristics of participants (n=40) 
Cognitive and Functional Assessment Scores  Mean (SD)                  Median (IQR) 
MoCA
1
 total score (0-30) 
MoCA subtest scores: 
     Visuospatial/ executive (0-5) 
     Naming (0-3) 
     Attention (0-6) 
     Language (0-3) 
     Abstraction (0-2) 
     Delayed recall (0-5) 
     Orientation (0-6) 
 
 
 
 
 
 
 
20.33 (±2.02)               20 (4)  
 
2.4 (±0.90)                    2 (1) 
2.3 (±0.80)                    2.5 (1)  
5.33 (±0.97)                  6 (1) 
1.95 (±0.55)                  2 (0) 
1.5 (±0.55)                    2 (1) 
0.90 (±1.30)                  0 (2) 
5.28 (±0.75)                  5 (1) 
ACE-III
2
 total score (0-100) 
ACE-III subtest scores: 
     Attention/ orientation (0-18) 
     Memory (0-26) 
     Fluency (0-14) 
     Language (0-26) 
     Visuospatial (0-16) 
 65.98 (±9.81)                70 (17) 
 
14.18 (±2.57)                 14.5 (4) 
15.38 (±5.06)                 16 (7.75) 
5.58 (±2.27)                   5(3.75) 
18.75 (±4.20)                 19.5 (6.75) 
11.35 (±1.70)                 11 (3) 
EFPT
3
 total score (0-100) 
EFPT task scores: 
     Simple cooking (0-25) 
     Telephone usage (0-25) 
     Medication management (0-25) 
     Bill payment (0-25) 
EPFT construct scores: 
     Initiation (0-20) 
     Organisation (0-20) 
     Sequencing (0-20) 
     Judgement and safety (0-20) 
     Completion (0-20) 
 23.34 (±9.0)                   23.5 (11) 
 
5.55 (±2.88)                   5 (5) 
4.68 (±2.16)                   5 (2.25) 
4.18 (±2.32)                   4 (4) 
8.92 (±3.0)                     9 (4) 
 
0.61 (±1.39)                  0 (0) 
2.61 (±2.42)                  2 (3) 
10.45 (±2.87)                11(4.25) 
6.71 (±2.78)                  6.5 (4) 
2.97 (±1.95)                  3 (3) 
ACE-III = Addenbrooke’s Cognitive Examination; EFPT = Executive Function Performance Test; IQR = 
interquartile range; MoCA = Montreal Cognitive Assessment; SD = standard deviation. Note: MoCA
1
 – 
higher scores indicate better cognitive performance; ACE-III
2
- higher scores indicate better cognitive 
performance; EFPT
3
 – lower scores indicate better functional performance 
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3.5 Correlations between EFPT and Cognitive Screening Tests 
The correlation between EFPT total scores and MoCA/ ACE-III total scores was 
calculated using Spearman’s rank-order correlational coefficient test for non-
parametric data. A p-value of less than 0.05 was considered to indicate statistical 
significance and all reported p-values were two-sided. Results showed a small non-
significant negative correlation between EFPT total scores and MoCA total scores 
(r= -0.22, p<0.19). There was a moderate negative significant correlation between 
EFPT total scores and ACE-III total scores (r= -0.41, p <0.05). Table 3.3 shows 
Spearman’s correlations between EFPT total scores and cognitive screening test total 
scores. Furthermore, Figures 3.2 and 3.3 show scatter plot diagrams of the 
relationship between EFPT total scores and MoCA/ACE-III total scores. 
 
Table 3.3 Correlations between EFPT and cognitive screening tests 
Cognitive Screens Correlation Co-
efficient 
 
Sig Intensity of 
Correlation 
MoCA -0.22 
 
0.19 Small negative     
ACE-III -0.41 
 
0.05** Moderate negative  
ACE-III = Addenbrooke’s Cognitive Examination; EFPT= Executive Function Performance Test; 
MoCA = Montreal Cognitive Assessment; Sig = significance. 
** Correlation is significant at the 0.05 level (2-tailed). 
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Figure 3.2 Scatter plot diagram of the relationship between EFPT total 
scores and MoCA total scores 
 
 
Figure 3.3 Scatter plot diagram of the relationship between EFPT total 
scores and ACE-III total scores 
  32   
 
3.6 Correlations between EFPT Scores and Cognitive Subdomains of the 
MoCA and ACE-III  
Spearman’s rank-order correlational coefficient was used to examine the relationship 
between EFPT scores and individual cognitive subdomains of the MoCA and ACE-
III tests. There were significant moderate negative correlations between the 
visuospatial/ executive subdomain of the MoCA and EFPT total score (r= -0.35, p< 
0.03), cooking oatmeal (r= -0.32, p<0.05), telephone usage (r= -0.37, p<0.02) and 
bill payment (r= -0.37, p<0.02) subscales. The memory domain of the ACE-III also 
showed significant moderate negative correlations with EFPT total score (r= -0.44, 
p<0.01), cooking oatmeal (r= -0.35, p<0.03) and bill payment (r= -0.33, p<0.05) 
subscales. Furthermore, there were significant large negative correlations between 
the visuospatial section of the ACE-III and EFPT total score (r= -0.54, p< 0.01) and 
all four subscales of cooking oatmeal (r= -0.53, p<0.01), telephone usage (r= -0.61, 
p<0.01), medication management (r= -0.50, p<0.01) and bill payment (r= -0.52, 
p<0.01) subscales. Table 3.4 shows Spearman’s correlations between EFPT scores 
and individual cognitive subdomains of the MoCA and ACE-III. 
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Table 3.4 Correlations between EFPT and individual cognitive subdomains 
of the MoCA and ACE-III Tests 
 Cooking 
Oatmeal 
Telephone 
Usage 
Medication 
Management 
Bill Payment Total 
MoCA      
Visuospatial/ Executive -0.32* -0.37* -0.24 -0.37* -0.35* 
Naming -0.04 -0.08  0.04 -0.01 -0.02 
Attention  0.04  0.11 -0.06  0.02  0.11 
Language -0.04 -0.05 -0.04  0.13  0.08 
Abstraction  0.13 -0.03 -0.05  0.04  0.10 
Delayed Recall -0.09 0.24 -0.05 -0.02 -0.06 
Orientation -0.15 0.04 -0.20 -0.10 -0.14 
Total -0.26 -0.06 -0.28 -0.25 -0.22 
ACE-III      
Attention/ orientation -0.10 0.07 -0.12 -0.07 -0.03 
Memory -0.35* -0.30 -0.29 -0.33* -0.44** 
Fluency -0.09 -0.01 0.13 -0.01  0.02 
Language -0.24 -0.26 -0.13 -0.31 -0.26 
Visuospatial -0.53** -0.61** -0.50** -0.52** -0.54** 
Total 0.43** -0.33* -0.28 -0.42** -0.41** 
ACE-III = Addenbrooke’s Cognitive Examination; EFPT = Executive Function Performance Test; 
MoCA = Montreal Cognitive Assessment 
** Correlation is significant at the 0.01 level (2-tailed). 
* Correlation is significant at the 0.05 level (2-tailed). 
 
3.7 The Influence of Various Cognitive and Demographic Factors on EFPT 
Scores 
Univariable linear regression analysis was conducted to explain the relationship 
between EFPT scores and the independent variables of age, gender, education level, 
number of medications, number of comorbidities, MoCA total score and ACE-III 
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total score. ACE-III total scores explained 19% of variance in EFPT scores as 
indicated by the highest r² value. The independent variables of age and gender 
explained 11% and 10% of variance respectively in participants’ EFPT scores. 
MoCA total scores explained just 6% of variance in the EFPT. This means that 94% 
of variance in EFPT scores can be attributed to factors other than those captured in 
the MoCA test. Table 3.5 shows full details of the univariable regression analysis. 
 
Table 3.5  Univariable linear regression analysis examining the influence of 
various cognitive and demographic variables on EFPT scores 
 R r²   % p-value 
Age 0.33 0.11 11% 0.04* 
Gender 0.32  0.10 10% 0.05* 
Education 0.17 0.03 3% 0.32 
No. of Medications 0.14 0.02 2% 0.42 
No. of Comorbidities 0.08 0.01 1% 0.64 
MoCA Total Score 0.25 0.06 6% 0.13* 
ACE-III Total Score 0.43 0.19 19% 0.01* 
EFPT = Executive Function Performance Test; r = correlation coefficient; r² = coefficient of 
determination; p-value = significance; % = percentage shared variance, No= number 
 
*Variable is significant at the 0.15 level. 
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3.8 Multivariable Regression Model 
Independent variables of age, gender, ACE-III total score and MoCA total score 
were entered into a multivariable linear regression model as they were significant at 
the 0.15 level in the univariable regression analysis. The multivariable regression 
model was used to examine whether any of these cognitive or demographic factors 
were independently associated with EFPT scores.  These independent variables 
together explained 35% of the variability in EFPT scores, meaning that 65% of 
variance in EFPT scores was attributed to factors other than age, gender, ACE-III 
total scores and MoCA total scores. Variables of gender (beta=-0.39, p<0.02) and 
ACE-III total score (beta=-0.55, p<0.01) remained significantly independently 
associated with EFPT scores in the multivariable linear regression analysis. Table 
3.6 shows the multivariable model. 
 
Table 3.6  Multivariable regression model  
 
Age 0.07 0.66 
Gender -0.39 0.02* 
ACE-II total score -0.55 0.01** 
MoCA total score 0.16 0.39 
 
* Correlation is significant at the 0.05 level (2-tailed). 
** Correlation is significant at the 0.01 level (2-tailed). 
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3.9 Summary of Results 
 Low correlations were observed between EFPT total scores and overall 
performance on the MoCA cognitive screen. 
 Significantly moderate correlations were observed between EFPT total scores 
and overall performance on the ACE-III cognitive screen. 
 The visuospatial/ executive domain of the MoCA was significantly 
moderately correlated to EFPT total score along with subscales of cooking 
oatmeal, telephone usage and bill payment. 
 The memory domain of the ACE-III was significantly moderately correlated 
to EFPT total score and subscales of cooking oatmeal and bill payment. 
 The visuospatial domain of the ACE-III was significantly largely correlated 
to EFPT total score and all four subscales of cooking oatmeal, telephone 
usage, medication management and bill payment. 
 Variables of gender and ACE-III total scores were significantly 
independently associated with EFPT scores in a multivariable regression 
model. 
 The results of the study will be discussed in greater detail in Chapter 4. 
 
  37   
 
CHAPTER 4 DISUCSSION 
 
4.1 Introduction 
The aim of the current study was to explore the relationship between cognitive test 
performance and IADL function in older adults with MCI in the acute hospital 
setting. The results demonstrated low-moderate correlations between EFPT total 
scores and MoCA/ ACE-III total scores. The visuospatial component of the ACE-III 
tool was consistently and largely correlated with EFPT total scores and all four 
subscale scores. Domains of memory and executive function were also moderately 
correlated with IADL performance as measured by the EFPT. A multivariable 
regression model showed that variables of gender and ACE-III total scores were 
significantly independently associated with EFPT scores. 
 
4.2 Review of Participants’ Demographic Characteristics 
The baseline demographic characteristics of the study participants were comparable 
to related studies (Aretouli and Brandt, 2010; Reppermund et al., 2011; Vermeersch 
et al., 2015). Similar to results found by Reppermund et al. (2011) and Vermeersch 
et al. (2015), the mean (±SD) age of the sample was 79.9 (±8.1), with the majority 
being female. The median (IQR) number of co-morbidities was 4 (2). There was a 
high level of poly-pharmacy (≥ 4 medications, 85%, n=34). The most common 
presenting condition of participants was that of a fall/ collapse. The World Health 
Organisation (2007) state that falls are a common reason for hospital admission 
amongst older adults.  
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4.3 Review of Participants’ Clinical Characteristics 
The study sample comprised a heterogeneous group of older adults with MCI in the 
acute hospital setting. The median (IQR) MoCA total score for the sample was 20(4) 
whereby scores of 18-25/30 indicate mild cognitive impairment. This demonstrates 
that the majority of participants were in the later stages of MCI. Nasreddine et al. 
(2005) provided normative data for the MoCA test and found that score of 22.12 is 
the norm for individuals with MCI. The median (IQR) ACE-III total score for the 
sample was 70(17) whereby the total score range is 0-100 and higher scores indicate 
better cognitive functioning. The mean (±SD) ACE-R score for patients with MCI in 
a study by Mioshi et al. (2006) was 84.2 (±7.3), again indicating that the population 
of the current study may be more cognitively impaired than MCI populations in 
related studies. The large IQR of ACE-III scores in the current study indicate that 
there was a wide spread of ACE-III scores amongst participants. The mean (±SD) 
EFPT total score for the sample was 23.3 (±9.0). EFPT total scores range from 0-100 
whereby lower scores indicate better functional performance.  
 
4.4 IADL Deficits in MCI 
The mean (±SD) EFPT total score of 23.3 (±9.0) in this study indicated that the 
sample had mild functional deficits. This is in line with a growing body of evidence 
which states that individuals with MCI demonstrate mild deficits in IADL 
functioning (Aretouli and Brandt, 2010; Marshall et al., 2011; Reppermund et al., 
2011; Vermeersch et al., 2015). There has been controversy as to whether functional 
deficits should be included in the diagnostic criteria for MCI (Giovannetti et al., 
2008).  Results of the current study support recent research stating that IADL 
impairment should be added to the diagnostic criteria for MCI.  
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Findings from the current study highlight the need for OTs to consider IADL 
function when assessing older adults with MCI in the acute hospital setting. 
Participants in the current study had most difficulty with the bill payment (mean 
8.92, ±SD 3.0) and cooking (mean 5.55 ±SD 2.88) subtests of the EFPT. The score 
range for each subtest is 0-25 with lower scores indicating better functional 
performance. The main areas of executive functioning which were impaired in the 
current study were those of judgement/ safety (mean 6.71 ±SD 2.78) and sequencing 
(mean 10.45, ±SD 2.87). The score range for each of the executive function 
component scores is 0-25 with lower scores indicating better executive functioning. 
The functional and executive deficits demonstrated by MCI patients in the current 
study are similar to the findings of previous studies. Research has consistently shown 
that financial management is impaired in MCI (Griffith et al., 2003; Jekel et al., 
2015) which parallels the results of the current study. Giovannetti et al. (2008) found 
that IADL deficits in MCI were related to inefficient and imprecise execution of task 
steps which is reflected by poor sequencing scores in the current study. Furthermore, 
Ciro et al. (2015) suggested that IADL deficits in MCI were related to adequacy and 
quality of task performance rather than safety and independence. This is in contrast 
to the results of the current study where the judgement/ safety domain was one of the 
executive skills in which participants were most impaired. 
 
4.5 Relationship between IADL Function and Global Cognitive Screens 
The MoCA and ACE-III tests were used in the current study to assess global 
cognitive functioning. These tools are commonly used by OTs in acute hospital 
settings as they are quick and easy to administer, screen several cognitive domains 
and are based on good clinical practice with geriatric populations (Vermeersch et al., 
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2015). The current study found a low non-significant correlation between MoCA 
total scores and EFPT total scores. A moderate significant correlation was found 
between ACE-III total scores and EFPT total scores. The ACE-III had a stronger 
relationship with IADL function than the MoCA. This may be secondary to the fact 
that the ACE-III has a greater number of subtests focusing on higher-level cognitive 
skills such as visuospatial integration and executive functioning. The results of the 
current study support use of the ACE-III rather than the MoCA when assessing 
individuals with MCI in the acute hospital setting due to its stronger relationship to 
functional status.  
 
The overall low-moderate relationship between cognitive test performance and 
functional abilities in the current study is in line with previous research. Royall et al. 
(2007) found that cognition only explained 21% of variance in functional outcomes 
in a meta-analysis of 68 studies. The univariable regression analysis conducted in the 
current study showed that the ACE-III explained 19% of variance in EFPT scores 
and the MoCA only explained 6% of variance EFPT scores. The low variance in 
functional status explained by cognitive screening tools is likely due to the fact that 
ADL function is multi-dimensional and depends on a combination of person, 
environment and task-specific factors (Marcotte and Grant, 2009). 
 
The findings of the current study add to the existing literature on the relationship 
between global cognitive tests and functional domains in MCI and dementia 
populations. There is a general lack of consensus in the literature regarding the 
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strength of the relationship between cognitive screening tests and functional status. 
An explorative study by Vermeersch et al. (2015) found moderate to large negative 
correlations (ranging from r= -0.28 to -0.61) between IADL function and global 
cognitive measures for individuals with AD, MCI and healthy controls. These 
findings contrast the findings from the current study whereby low-moderate 
correlations were evident. However, the differing results may due to the fact that the 
cognitive and functional measures used in the study by Vermeersch et al. (2015) 
(MMSE, CAMCOG, Advanced Activities of Daily Living Tool) were more 
simplistic and less reliant on high-cognitive demand. 
 
Furthermore, Yantz et al. (2010) examined the relationship between cognitive test 
performance and performance on a standardised cooking task (Rabideau Kitchen 
Evaluation, RKE) within a stroke population. Spearman’s correlations between the 
functional task of meal preparation and the MMSE cognitive screen showed a large 
negative correlation (r=-0.73) indicating a strong relationship between the MMSE 
cognitive screen and the functional task of cooking. This stands in contrast to the 
results of the current study whereby low-moderate correlations were found between 
cognitive test performance and IADL function. This contrast may be due to the 
differences in cognitive and functional assessment tools used as the MMSE and RKE 
appear to be less cognitively-demanding when compared to the MoCA, ACE-III and 
EFPT, particularly in relation to executive cognition and visuospatial skills.  
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Results from a study by Toglia et al. (2011) revealed that both the MoCA and 
MMSE cognitive screens demonstrated moderate correlations with discharge 
functional status, with the MoCA showing marginally stronger associations (r=0.40; 
P<0.01) than the MMSE (r=0.30; P<0.05). The relationship between the MoCA and 
IADL function in the current study was slightly lower (r= -0.22, p<0.19) when 
compared the study by Toglia et al. (2011). It is important to note that the MMSE 
relies on several cognitive abilities however it does not examine executive function 
components which are proven to be important for IADL task completion.  
 
The current study provided a broad overview of the relationship between 
performance on global cognitive screening tests and IADL function in older adults 
with MCI in the acute hospital setting. It addressed the identified gap in the literature 
as it utilised cognitive screening tools that are commonly used by OTs in the acute 
hospital setting (MoCA and ACE-III) in addition to a standardised assessment of 
IADL function (EFPT). However, it is evident that comparison with previous related 
studies is difficult secondary to the variability in global cognitive screening tools and 
functional assessments used. 
 
4.6 Relationship between IADL Function and Cognitive Subdomains 
The results of the current study demonstrated that a range of specific cognitive 
domains are relevant to performance of IADLs including memory, executive 
function and visuospatial skills. This is not surprising given the cognitively diverse 
nature of IADL tasks. The present study found moderate correlations between IADL 
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function and the cognitive domain of visuospatial/ executive skills on the MoCA in 
addition to the memory domain of the ACE-III. The current study also found that the 
visuospatial component of the ACE-III was significantly largely correlated with 
EFPT total scores in addition to all functional subcomponent of cooking, telephone 
usage, medication management and bill payment.  
 
Findings from the current study demonstrate the link between underlying memory, 
executive and visuospatial components on the functional execution of several IADL 
tasks such as cooking, telephone usage, mediation management and bill payment. 
This highlights the importance of ensuring that assessment of such underlying 
cognitive skills is completed in clinical practice when working with older adults with 
MCI. The current study adds important evidence to the literature as it encourages 
healthcare professionals to examine patients’ performance in subdomains of 
cognitive screens rather than just looking the total score. 
 
The current study suggests that different cognitive domains may be important for 
different IADL tasks. Results showed that cooking and bill payment were most 
strongly related to visuospatial, executive and memory skills; telephone usage was 
most strongly related to visuospatial and executive skills and medication 
management was most strongly related to visuospatial skills. Marcotte and Grant 
(2009) suggested that measures of executive functioning were related with driving 
behaviour whereas working memory appeared to be strongly associated with money 
management. While findings from the current study support this link between 
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memory and money management, the current study also found that visuospatial 
abilities as measured in both MoCA and ACE III were significantly correlated with 
money management. Furthermore, Yantz et al. (2010) found that several cognitive 
domains from neuropsychological testing were significantly related to functional 
cooking skills in patients with stroke. Results suggested that functional cooking task 
performance was related to intact cognitive abilities in the domains of delayed verbal 
memory, simple auditory attention and visuospatial skills as well as overall global 
cognitive performance. These results are similar to the findings from the current 
study. 
 
Research has shown that executive skills are related to functional capacity. The 
current study found that the executive subdomain of the MoCA was moderately 
related to IADL function as measured by the EFPT. Research by Bell-McGinty et al. 
(2002) found that executive skills explained a large variance in functioning (up to 
54%) in a group of older adults. However it’s important to note that Bell-McGinty et 
al. (2002) did not control for overall cognitive abilities when investigating the 
relationship between executive functions and performance on ADLs and it could 
therefore be argued that the global cognitive measures obscured the true influence of 
the specific domain of executive functioning. In contrast to the results of the study 
by Bell-McGinty et al. (2002), a meta-analysis conducted by Royall et al. (2007) 
found a small to modest variance in functional outcome explained by executive 
function and general cognitive measures. Unfortunately each individual cognitive 
subdomain of the MoCA and ACE-III tests could not be placed in the regression 
model of the current study due to the relatively small sample size.  
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Similar to the current study, Aretouli and Brandt (2010), De Paula and Malloy-Diniz 
(2013) and Hanks et al. (1999) found that executive skills were related to functional 
capacity. Aretouli and Brandt (2010) examined everyday functioning in MCI and its 
relationship with the executive function skills of planning/ problem-solving, working 
memory and judgement. Results demonstrated that one executive function 
component (working memory) contributed significantly to functional status after 
controlling for demographic, health-related and other cognitive factors.  In addition, 
Hanks et al. (1999) demonstrated that executive functioning and verbal memory 
were strongly related to functional outcome six months following discharge from 
rehabilitation in a sample of 90 participants with TBI, orthopaedic and spinal cord 
injury diagnoses. Similarly, De Paula and Malloy-Diniz (2013) found that executive 
function skills were significantly related to functional status in older adults with mild 
AD or MCI (n=118), accounting for approximately 30% of variance in function.  
 
A body of research has shown that memory and learning are strong predictors of 
functional capacity (Gross et al., 2012; Marcotte and Grant, 2009). The current study 
reflects this as the ACE-III domain of memory was significantly related to EFPT 
total score and subtests of cooking oatmeal and bill payment. Results from a study 
by Toglia et al. (2011) showed that the MMSE memory subtests of orientation, 
registration and recall were predictive of the FIM physical subscale and motor 
relevant functional efficiency in a study of 72 participants post stroke.  In addition, 
Vermeersch et al. (2015) demonstrated that the memory section of the CAMCOG 
reflected the strongest associations with functional decline. In addition, Springate 
and Tremont (2012) found that the Minnesota Cognitive Acuity Screen orientation 
subscale was one of the strongest subscales in predicting functional status in the 
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sample of participants with dementia or MCI as it was uniquely predictive of all 
Clinical Dementia Rating Scale domains. 
 
The current study showed that a range of cognitive domains are related to IADL 
function as measured by the EFPT. This is in agreement with findings from a study 
by Farias et al. (2003) who examined the relationship between neuropsychological 
performance and daily functioning in individuals with AD. This study found that 
domains of apraxia, visual spatial abilities, immediate memory and executive 
function were most frequently correlated with the functional domains of the Direct 
Assessment of Functional Status tool. In addition, domains of immediate memory, 
executive function, confrontation naming and apraxia were most consistently related 
with the functional domains of the Instrumental Activities of Daily Living measure. 
It is important to note that a wide variety of cognitive and functional assessment 
tools were used in previous research and these measured many different constructs 
which makes comparison between studies difficult.  
 
The EFPT tool used in the current study provided a comprehensive assessment of 
executive functions and overall IADL functional capacity however it was lengthy to 
administer. Furthermore, it did not examine everyday technology, an IADL that is 
becoming more relevant to individuals with MCI. Further research is required 
regarding development of a psychometrically-sound, straightforward, time-efficient 
screening tool that will assist OTs in assessment, rehabilitation and discharge 
planning for individuals with MCI in the acute hospital setting.  
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4.7 Additional Factors Associated with IADL Function 
Multivariable regression analysis completed in the current study showed that only 
35% of variance in IADL function was attributed to the demographic and cognitive 
variables of age, gender, MOCA total score and ACE-III total score. This indicates 
that 65% of IADL is explained by other factors. Joliffe et al. (2015) highlighted that 
many factors impact on an individual’s occupational functioning and performance in 
addition to cognition such as physical skills and mood. Furthermore, Vermeersch et 
al. (2015) stated that functional capacity is associated with a variety of factors other 
than cognition such as physical, emotional and social variables. Marcotte and Grant, 
(2009) found that cognitive impairment can lead to cognitive deficits, however this 
still depends on a combination of the person, environment and occupational specific 
factors. This complexity may explain why cognitive test performance alone did not 
fully explain the functional capabilities of the participants in the current study.  
 
4.8 Clinical Relevance  
The findings of the current study have important implications for clinical practice. 
An important finding of the study is that IADL function can be impaired in 
individuals with MCI. Although the functional impairments in MCI are typically not 
as severe as dementia, MCI patients may still require assistance with more 
cognitively-demanding daily activities. This highlights the importance of addressing 
IADL function among patients with MCI in the acute hospital setting to optimise 
assessment, rehabilitation, discharge planning and healthcare policy. Furthermore, 
results of this study are in agreement with recent body of empirical evidence stating 
that mild IADL deficits should be included in the diagnostic criteria for MCI.  
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The current study also found that the MoCA and ACE-III cognitive screening tools 
had a poor-modest relationship with EFPT scores in older adults with MCI. This 
low-moderate relationship makes clinical sense. Patients often perform better on 
cognitive screening tests compared with functional tasks and vice versa. It is evident 
that use of cognitive screens alone is not sufficient to allow clinical decisions to be 
made regarding functional capacity of individuals with MCI. The use of functional 
assessment is crucial in assisting clinicians to fully understand the functional 
capabilities of this client group.  
 
Domains of memory, executive functioning and visuospatial skills had a moderate-
large relationship with EFPT scores in older adults with MCI in this study. This 
highlights the importance of interpreting scoring patterns on cognitive screening 
tools rather than just examining the total score. OTs should ensure careful 
assessment of these cognitive skills in individuals with MCI due to their association 
with functional impairments. A combination of cognitive and functional assessments 
may be useful in comprehensively assessing older adults with MCI in the acute care 
setting.  
 
IADL function is multi-dimensional and depends on a combination of person, 
environment and task specific factors (Marcotte and Grant, 2009). This complexity 
can help explain why cognitive testing alone may not fully explain an individual’s 
ability to perform IADL tasks.  Most of the variability in functional performance 
could not be explained in the multivariable regression model used in the current 
study. For good clinical practice in OT within the acute care setting, the author 
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recommends objective evaluation of IADLs in addition to use of cognitive screening 
tests. This should enhance the detection of subtle functional deficits in early 
cognitive decline.  
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4.9 Limitations of the Study 
 This study employed a cross-sectional design and therefore cannot reveal any 
direction of causality in the relationship between performance on cognitive 
screening tests and IADL function. Results from the correlational and 
regression analyses cannot be interpreted as establishing cause and effect 
relationships. 
 
 This study was conducted in a one centre and participants were recruited 
from one geographical region. The demographic characteristics of 
participants in this setting may not reflect those in other acute hospitals in 
Ireland. Therefore, the results may not be applicable to other acute hospitals. 
  
 The study sample was a non-random sample of convenience, with a higher 
proportion of women. Use of convenience sampling means that the 
opportunity to participate in the study was not equal for all individuals in the 
target population and study results are not necessarily generalisable to this 
population. In addition, the small sample size affected the number of 
variables that could be explored in the multiple regression analysis.  
 
 The selection criteria for defining MCI may be questioned, since there is no 
universally accepted prescription for how the Peterson (2004)/ Winblad et al. 
(2004) criteria should be operationalised.  
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 The functional assessment (EFPT) tool was timely to complete in a fast-
paced acute hospital setting. Furthermore, performance-based functional 
assessment tools can have limitations i.e. they are more labour intensive to 
administer. Future research should explore different functional assessment 
tools that may be more time-efficient to use within the acute hospital setting 
would.  
 
 The study took place in the acute hospital setting whereby individuals were 
recovering from acute illness. Although measures were taken to best manage 
this in terms of selection criteria, it may have impacted on participants’ 
performance and overall results. Recovery from acute illness, change of 
medications and an unfamiliar environment are factors that need to be taken 
into account when interpreting the results.  
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4.10 Recommendations for Future Research 
 Future research should include a large multi-centre study. Participants could 
be recruited from a larger geographical area, including a variety of public and 
private hospital systems, utilising random sampling methods. This would 
assist policy makers in planning and delivering effective services to address 
the needs of older adults with MCI in the acute hospital setting.  
 
 A longitudinal component could be added to the study e.g. gathering 
information on discharge location and functional status six months post 
admission. A longitudinal study would capture the relationship between 
cognitive test performance and functional status over time and explore 
whether functional impairment on specific IADLs are predictors of further 
cognitive decline. 
 
 It would be beneficial to explore the relationship between cognitive test 
performance and functional status in other clinical populations e.g. dementia, 
Parkinson’s disease, brain injury. Further research should also include 
evaluation of depressive symptoms and their impact on functional 
performance.  
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CONCLUSION  
This study explored the relationship between performance on cognitive screening 
tests and IADL function in older adults with MCI in the acute care setting. Based on 
the results, the author recommends that cognitive screening tools should not be used 
in isolation during the process of cognitive assessment for individuals with MCI. The 
ACE-III test should be used appropriately in conjunction with objective evaluation 
of ADL functioning to generate a comprehensive profile of a patient’s abilities. This 
study highlights the value of observation of actual functioning within a task and 
proves that cognitive screening alone cannot be used to make conclusions regarding 
occupational performance. Furthermore, the results help underline the importance of 
interpreting the scoring patterns on cognitive screening tests rather than just 
examining the overall score as certain cognitive domains appear to be more strongly 
related to IADL function than others.  
 
The results from this study provide clinicians with a better understanding of the 
relationship between performance on cognitive screening tests and IADL function 
amongst older adults with MCI in the acute hospital setting. This study contributes to 
the body of existing empirical evidence investigating the relationship between 
cognitive and functional domains. The results impact on clinical practice and 
highlight the importance of OT in the cognitive and functional evaluation for 
individuals with MCI.  
 
WORD COUNT: 10,863 
  54   
 
 
American Occupational Therapy Association. (2013). Cognition, cognitive 
rehabilitation and occupational performance. The American Journal of Occupational 
Therapy, 67, 59-67. 
 
American Psychiatric Association. (2013). Diagnostic and Statistical Manual of 
Mental Disorders (5
th
 edition). Washington, DC: American Psychiatric Publishing. 
 
Albert, M.S., Dekosky, S. T., Dickson, D., Dubois, B., Feldman, H. H, Fox, N. C. 
and Phelps, C. H. (2011). The diagnosis of mild cognitive impairment due to 
Alzheimer’s disease: Recommendations from the National Institute on Ageing and 
Alzheimer’s Association workgroup. Alzheimer’s and Dementia, 7 (3), 270-279. 
 
Aretouli, E. and Brandt, J. (2010). Everyday functioning in mild cognitive 
impairment and its relationship with executive cognition. International Journal of 
Geriatric Psychiatry, 25 (3), 224-233. 
 
Baum, C., Edwards, D., Yonan, C. and Storandt, M. (1996). The relation of 
neuropsychological test performance to performance of functional tasks in dementia 
of the Alzheimer type. Archives of Clinical Neuropsychology, 11 (1), 69-75. 
 
  55   
 
Baum, C. M. and Edwards, D. (1993). Cognitive performance in senile dementia of 
the Alzheimer’s type: The kitchen task assessment. American Journal of 
Occupational Therapy, 47, 431-436. 
 
Baum, C. M., Morrison, T., Hahn, M. and Edwards, D. F. (2003). Test Manual: 
Executive Function Performance Test. St Louis, MO: Washington University. 
 
Baum, C. M., Morrison, T., Hahn, M. and Edwards, D. F. (2007). Executive 
Function Performance Test: Test protocol booklet. St Louis, MO: Washington 
University. 
 
Baum, C. M., Connor, L. T., Morrison, T., Hahn, M., Dromerick, A. W. and 
Edwards, F. (2008). Reliability, validity and clinical utility of the executive function 
performance test: a measure of executive function in a sample of people with stroke. 
American Journal of Occupational Therapy, 62, 446-455. 
 
Belchior, P., Holmes, M., Bier, N., Bottari, C., Mazer, B., Robert, A. and Kaur, N. 
(2015). Performance-based tools for assessing functional performance in individuals 
with mild cognitive impairment. The Open Journal of Occupational Therapy, 3 (3). 
 
  56   
 
Bell-McGintyS., Podell, K., Franzen, M., Baird, A. D. and Williams, M. J. (2002). 
Standard measures of executive function in predicting instrumental activities of daily 
living in older adults. International Journal of Geriatric Psychiatry, 17 (9), 828-834. 
 
Borbosi, S., Jones, J., Lockwood, C. and Emden, C. (2006). Health professionals 
perspectives of providing care to people with dementia in the acute setting: toward 
better practice. Geriatric Nursing, 27 (5), 300-308. 
 
Brookmeyer, R., Evans, D. A., Hebert, L., Langa, K. M., Heeringa,S. G., Plassman, 
B. L. and Kukull, W. A. (2011). National estimates of the prevalence of Alzeihmers 
disease in the United States. Alzheimer’s and Dementia, 7 (1), 61-73. 
 
Brown, T., Mapleston, J., Nairn, A. and Molloy, A. (2013). Relationship of cognitive 
and perceptual abilities to functional independence in adults who have had a stroke. 
Occupational Therapy International, 20 (1), 11-22. 
 
Burton, C. L., Strauss, E., Bunce, D., Hunter, M. A. and Hultsch, D.F. (2009). 
Functional abilities in older adults with mild cognitive impairment. Gerontology, 55 
(5), 570-581. 
 
  57   
 
Carpenter, C. R., Bassett, E. R., Fischer, G. M., Shirshekan, J., Galvin, J. E. and 
Morris, J. C. (2011). Four sensitive screening tools to detect cognitive dysfunction in 
geriatric emergency department patients. Academic Emergency Medicine, 18 (4), 
374-384. 
 
Cederfeldt, M., Widell, Y., Elgmark-Anderson, E., Dahlin-Ivanoff, S. and Gosman-
Hedstrom, G. (2011). Concurrent validity of the Executive Function Performance 
Test (EFPT) in people with mild stroke. The British Journal of Occupational 
Therapy, 74 (9), 443-449. 
 
Cederfeldt, M., Carlsson, G., Dahlin-Ivanoff, S. and Gosman-Hedstrom, G. (2015). 
Inter-rater reliability and face validity of the Executive Function Performance Test 
(EFPT). The British Journal of Occupational Therapy, 78 (9), 563-569.  
 
Ciro, C. A., Anderson, M. P., Hershey, L. A., Prodan, C. I. and Holm, M. B. (2015). 
Instrumental activities of daily living performance and role satisfaction in people 
with and without mild cognitive impairment: a pilot project. The American Journal 
of Occupational Therapy, 69 (3). 
 
Cohen, J. (1988). Statistical power analysis for the behavioural sciences (2
nd
 
edition). Hillsdale, NJ: Erlbaum. 
 
  58   
 
Conroy, R. (2009). Sample Size: A Rough Guide. Available at: 
http://www.beaumontethics.ie/docs/application/samplesizecalculation.pdf 
[accessed 15 October 2015]. 
 
Crawford, S., Whitnall, L., Robertson, J. and Evans, J. J. (2012). A systematic 
review of the accuracy and clinical utility of the Addenbrooke’s Cognitive 
Examination and the Addenbrooke’s Cognitive Examination – Revised in the 
diagnosis of dementia. International Journal of Geriatric Psychiatry, 27 (7), 659-
669. 
 
Data Guidance on Research in Health Sector. (2007). Available at: 
http://www.dataprotection.ie/documents/guidance/Health_research.pdf [accessed 
15th June 2015]. 
 
Data Protection Act. (2003). Available at: http://www.ico.gov.uk [accessed 15
th
 June 
2015]. 
 
De Paula, J. J. and Malloy-Diniz, L. F. (2013). Executive functions as predictors of 
functional performance in mild Alzheimer’s dementia and mild cognitive 
impairment. Estudos de Psicologia, 18 (1), 117-124. 
 
  59   
 
Elliott, R. A. and Marriott, J. L. (2009). Standardised assessment of patients’ 
capacity to manage medications: a systematic review of published instruments. BMC 
Geriatrics, 9 (27), 1-10. 
 
Farias, S. T., Harrell, E., Neumann, C. and Houtz, A. (2003). The relationship 
between neuropsychological performance and daily functioning in individuals with 
Alzheimer’s disease: ecological validity of neuropsychological tests. Archives of 
Clinical Neuropsychology, 18, 655-672. 
 
Faucounau, V., Wu, Y. H., Boulay, M., Rotrou, J. and Rigaud, A. S. (2010). 
Cognitive intervention programmes on patients affected by mild cognitive 
impairment: a promising intervention tool for MCI? The Journal of Nutrition Health 
and Aging, 14 (1), 31-35. 
 
Freitas, S., Simoes, M. R., Alves, L., Duro, D. and Santana, I. (2012). Montreal 
cognitive assessment: validation study for frontotemporal dementia. Journal of 
Geriatric Psychiatry and Neurology, 25 (3), 146-154. 
 
Galvin, J. E., Fagan, A. M., Holtzman, D. M., Mintun, M. A. and Morris, J. C. 
(2010). Relationship of dementia screening tests with biomarkers of Alzheimer’s 
disease. Brain, 133 (11), 3290-3300. 
 
  60   
 
Gifford, J. and Jones, R. (2009). Assessment and treatment of cognitive deficits in 
dementia. Prescriber, 20 (6), 45-49. 
 
Gillen, G. (2009). Cognitive and perceptual rehabilitation: optimising function. St 
Louis Mo: Mobsy. 
 
Giovannetti, T., Bettcher, B. M., Brennan, L., Libon, D. J., Burke, M., Duey, K., 
Nieves, C. and Wambach, D. (2008). Characterision of everyday functioning in mild 
cognitive impairment: A direct assessment approach. Dementia and Geriatric 
Cognitive Disorders, 25 (4), 359-365. 
 
Gold, D. A. (2012). An examination of instrumental activities of daily living 
assessment in older adults and mild cognitive impairment. Journal of Clinical and 
Experimental Neuropsychology, 34 (1), 11-34. 
 
Goldberg, T. E., Koppel, J., Keehlisen, L., Christen, E., Dreses-Werringloer, U., 
Conejero-Goldberg, C., Gordon, M. L. and Davies, P. (2010). Performance-based 
measures of everyday function in mild cognitive impairment. The American Journal 
of Psychiatry, 167 (7), 845-853. 
 
Goverover, Y., Chiaravalloti, N., Guadino-Goering, E., Moore, N. and DeLuca, J. 
(2009). The relationship among performance of instrumental activities of daily 
  61   
 
living, self-report of quality of life, and self-awareness of functional status in 
individuals with multiple sclerosis. Rehabilitation Psychology, 54 (1), 60-68. 
 
Griffith, H.R., Belue, K., Sicola, A., Krzywanski, S., Zamrini, E., Harrell, L. and 
Marson, D. C. (2003). Impaired financial abilities in mild cognitive impairment: a 
direct assessment approach. Neurology, 60 (3), 449-457. 
 
Gross, A. L., Parisi, J. M., Spira, A. P., Kueider, A. M., Ko, J. Y., Saczynski, J. S., 
Samus, Q. M. and Rebok, G. W. (2012). Memory training interventions for older 
adults: a meta-analysis. Aging and Mental Health, 16 (6), 722-734. 
 
Hanks, R. A., Rapport, L. J., Millis, S. R. and Deshpande, S. A. (1999). Measures of 
executive functioning as predictors of functional ability and social integration in a 
rehabilitation sample. Archives of Physical Medicine and Rehabilitation, 80, 1030-
1037. 
 
Hsieh, S., Schubert, S., Hoon, C., Mioshi, E. and Hodges, J. R. (2013). Validation of 
the Addenbrooke’s cognitive examination III in frontotemporal dementia and 
Alzheimer’s disease. Dementia and Geriatric Cognitive Disorders, 36, 242-250. 
 
  62   
 
IBM Corp. (2013). IBM SPSS Statistics for Windows, Version 22.0. Armonk, NY: 
IBM Corp. 
 
Jekel, K., Damian, M., Wattmo, C., Hausner, L., Bullock, R., Connelly, P. J., 
Dubois, B., Eriksdotter, M., Ewers, M., Graessel, E., Kramberger, M G., Law, E., 
Mecocci, P., Molinuevo, J. L., Nygard, L., Olde-Rikkert, M. G. M., Orgogozo, J. M., 
Pasquier, F., Peres, K., Salmon, E., Sikkes, S. A. M., Sobow, T., Spiegel, R., 
Tsolaki, M., Winblad, B. and Frolich, L. (2015). Mild cognitive impairment and 
deficits in instrumental activities of daily living: a systematic review. Alzheimer’s 
Research and Therapy, 7 (17), 2-20. 
 
Jenkins, S., Price, C. J. & Straker, L. (1998). The Researching Therapist: A Practical 
Guide to Planning, Performing and Communicating Research. New York: Churchill 
Livingstone.  
 
Joliffe, L., Brown, T. and Fieldling, L. (2015). Are clients’ performances on the 
Rowland Universal Dementia Assessment Scale associated with their functional 
performance? A preliminary investigation. The British Journal of Occupational 
Therapy, 78(1), 16-23. 
 
Julayanont, P., Philips, N., Chertkow, H. and Nasreddine, Z. S. (2012). The Montreal 
Cognitive Assessment (MoCA): Concept and Clinical Review. In: Larner, A. J.  
  63   
 
(Ed.), Cognitive Screening Instruments: A Practical Approach. New York: Springer-
Verlag.  
 
Kalmar, J. H., Gaudino, E. A., Moore, N. B. Halper, J., and DeLuca, J. (2008). The 
relationship between cognitive deficits and everyday functional activities in multiple 
sclerosis. The American Psychological Association, 22 (4), 442-449. 
 
Katz, N., Fleming, J., Keren, N., Lightbody, S. and Hartman-Maeir, A. (2002). 
Unawareness and/ or denial of disability: implications for occupational therapy 
intervention. Canadian Journal of Occupational Therapy, 69 (5), 281-292. 
 
Katz, N., Tadmore, I., Felzen, B. and Hartman-Maeir, A. (2007). Validity of the 
Executive Function Performance Test in individuals with schizophrenia. 
Occupational Therapy Journal of Research, 27, 1-8. 
 
Larner, A. J. (2007). Addenbrooke’s Cognitive Examination (ACE) for the diagnosis 
and differential diagnosis of dementia. Clinical Neurology and Neurosurgery, 109 
(6), 491-494. 
 
  64   
 
Lin, F., Vance, D. E., Gleason, C. E. and Heidrich, S. M. (2012). Taking care of 
older adults with mild cognitive impairment: An update for nurses. Journal of 
Gerontological Nursing, 38 (12), 22-37. 
 
Loewenstein, D. A., Rubert, M.P., Arguelles, T. and Duara, R. (1995). 
Neuropsychological test performance and prediction of functional capacities among 
Spanish-speaking and English-speaking patients with dementia. Archives of Clinical 
Neuropsychology, 10 (2), 75-88. 
 
Lorch, A. and Earland, T. V. (2015). Cognitive interventions for the client with mild 
neurocognitive disorder. Available at: 
files.abstractsonline.com/CTRL/33/2/734/365/094/4E3/7A3/022/81C/329/733/AA/a
2996_1.PDF. [accessed 10
th
 May 2015]. 
 
Luttenberger, K., Schmiedeberg, A. and Grabel, E. (2012). Activities of daily living 
in dementia: revalidation of the E-ADL test and suggestions for further development. 
BMC Psychiatry, 208 (12), 1-10. 
 
Marcotte, T. M. and Grant, I.  (2009). Neuropsychology of Everyday Functioning. 
New York: The Guildford Press. 
 
  65   
 
Marshall, G. A., Rentz, G. M., Frey, M. T., Locascio, J. J., Johnson, K. A. and 
Sperling, R. A. (2011). Executive function and instrumental activities of daily living 
in MCI and AD. Alzheimer’s and Dementia, 7 (3), 300-308. 
 
Matias-Guiu, J. A., Fernandez de Bobadilla, R., Escudero, G., Perez-Perez, J., 
Cortes, A., Morenas-Rodriguez, E., Valles-Salgado, M., Moreno-Ramos, T., 
Kulisevsky, J. and Matias-Guiu, J. (2015). Validation of the Spanish version of 
Addenbrooke’s Cognitive Examination III for diagnosing dementia. Neurologia, 30 
(9), 545-551. 
 
McCowan, C., Donnan, P., Dewar, J., Thompson, A. and Fahy, T. (2011). 
Identifying suspected breast cancer: development and validation of a clinical 
prediction rule. British Journal of General Practitioners, 61 (586), 205-214. 
 
Mioshi, E., Dawson, K., Mitchell, J., Arnold, R. and Hodges, J. R. (2006). The 
Addenbrooke’s cognitive examination revised: a brief cognitive test battery for 
dementia screening. Internal Journal of Geriatric Psychiatry, 21 (11), 1078-1085. 
 
Nasreddine, Z. S., Phillips, N. A., Bedirian, V., Charbonneau, S., Whitehead, V., 
Collin, I., Cummings, J. L. and Chertkow, H. (2005). The Montreal cognitive 
assessment: a brief screening tool for mild cognitive impairment. Journal of the 
American Geriatrics Society, 53 (4), 695-699. 
  66   
 
Okonkwo, O. C., Wadley, V.G., Griffith, H. R., Belue, K., Lanza, S., Zamrini, E. Y., 
Harrell, L.E., Brockington, J. C., Clark, D., Raman, R. and Marson, D. C. (2008). 
Awareness of deficits in financial abilities in patients with mild cognitive 
impairment: going beyond self-informant discrepancy. American Journal of 
Geriatric Psychiatry, 16 (8), 650-659. 
 
Perry, R. J. and Hodges, J. R. (2000). Relationship between functional and 
neuropsychological performance in early Alzheimer disease. Alzheimer’s disease 
and Associated Disorders, 14 (1), 1-10. 
 
Peterson, R. C. (2004). Mild cognitive impairment as a diagnostic entity. Journal of 
Internal Medicine, 256, 183-194. 
 
Peterson, R. C. (2011). Mild cognitive impairment. The New England Journal of 
Medicine, 364, 2227-2234. 
 
Reppermund, S., Sachdev, P. S., Crawford, J., Kochan, N.A., Slavin, M. J., Kang, 
K., Troller, J. N., Draper, B. and Brodaty, H. (2011). The relationship of 
neuropsychological function to instrumental activities of daily living in mild 
cognitive impairment. Internal Journal of Geriatric Psychiatry, 26, 843-852. 
 
  67   
 
Rodakowski, J., Skidmore, E. R., Reynolds, C. F., Dew, M. A., Butters, M. A., 
Holm, A. B., Lopez, O. L. and Rogers, J. C. (2014). Can performance of daily 
activities discriminate between older adults with normal cognitive function and those 
with mild cognitive impairment? Journal of the American Geriatrics Society, 62 (7), 
1347-1352. 
 
Royal, D. R., Lauterbach, E. C., Kaufer, D., Malloy, P., Coburn, K. L. and Black, K. 
J. (2007). The cognitive correlates of functional status: a review from the committee 
on research of the American neuropsychiatric association. The Journal of 
Neuropsychiatry and Clinical Neurosciences, 19 (3), 249-265. 
 
Ruff, R. M. (2003). A friendly critique of neuropsychology: facing the challenges of 
our future. Archives of Clinical Neuropsychology, 18, 847-864. 
 
Schmitter-Edgecombe, M., Woo, E. and Greeley, D. R. (2009). Characterizing 
multiple memory deficits and their relation to everyday functioning in individuals 
with mild cognitive impairment. Neuropsychology, 23 (2), 168-177. 
 
Sheehan, B. (2012). Assessment scales in dementia. Therapeutic Advances in 
Neurological Disorders, 5 (6), 349-358. 
 
  68   
 
Smith, T., Gildeh, N. and Holmes, C. (2007). The Montreal cognitive assessment: 
validity and utility in a memory clinic setting. Canadian Journal of Psychiatry, 52 
(5), 329-332. 
 
Springate, B. A. and Tremont, G. (2012). Predicting functional impairments in 
cognitively impaired older adults using the Minnesota Cognitive Acuity Screen. 
Journal of Geriatric Psychiatry and Neurology, 25 (4), 195-200. 
 
Toglia, J. and Kirk, U. (2000). Understanding awareness deficits following brain 
injury. Neurorehabilitation, 15(1), 57-70. 
 
Toglia, J., Fitzgerald, K. A., O’Dell, M. W., Mastrogiovanni, A. R. and Lin, C. D. 
(2011). The Mini-Mental State Examination and Montreal Cognitive Assessment in 
person with mild subacute stroke: relationship to functional outcome. Archives of 
Physical Medicine and Rehabilitation, 92 (5), 792-798.  
 
Trzepacz, P. T., Hochstetler, H., Wang, S., Walker, B. and Saykin, A. J. (2015). 
Relationship between the Montreal Cognitive Assessment and the Mini-Mental State 
Examination for assessment of mild cognitive impairment in older adults. BioMed 
Central Geriatrics, 15, 107.  
 
  69   
 
Valcour, V. G., Masaki, K. H., Curb, J. D. and Blanchette, P.L. (2000). The 
detection of dementia in the primary care setting. Archives of Internal Medicine, 160 
(19), 2964-2968. 
 
Vermeersch, S., Gorus, E., Cornelis, E. and De Vriendt, P. (2015). An explorative 
study of the relationship between functional and cognitive decline in older persons 
with mild cognitive impairment and Alzheimer’s disease. The British Journal of 
Occupational Therapy, 78(3), 166-174. 
 
Von Elm, E., Altman, D. G., Egger, M., Pocock, S. J., Gotzsche, P. C. and 
Vandenbroucke, J. P. (2008). The strengthening the reporting of observational 
studies in epidemiology (STROBE) statement: guidelines for reporting observation 
studies. Journal of Clinical Epidemiology, 61 (4), 344-349. 
 
Wajman, J. R., Schultz, R. R., Correia Marin, S. M. and Ferreira Bertolucci, P. H. 
(2014). Correlation and adaption among functional and cognitive instruments for 
staging and monitoring Alzheimer’s disease in advanced stages. Archives of Clinical 
Psychiatry, 41 (1), 5-8. 
 
Weintraub, S., Wicklund, A. H. and Salmon, D. P. (2012). The neuropsychological 
profile of Alzheimer disease. Cold Spring Harbor Perspectives in Medicine, 2, 1-18. 
 
  70   
 
Winblad, B., Palmer, K., Kivipelto, M., Jelic, V., Fratiglioni, L., Wahlund, L. O., 
Nordberg, A., Backman, L., Albert, M., Almkvist, O., Arai, H., Basun, H., Blennow, 
K., De Leon, M., Decarli, C.,Erkinjuntii, T., Giacobini, E., Graff ,C., Hardy, J., Jack, 
C., Jorm, A., Ritchie, K., Van Duijn, C., Visser, P. and Peterson, R. C. (2004). Mild 
cognitive impairment – beyond controversies, towards a consensus: report of the 
International Working Group on Mild Cognitive Impairment. Journal of Internal 
Medicine, 256, 240-246. 
 
Wolf, T. J., Stift, S., Connor, L. T. and Baum, C. (2010). Feasibility of using the 
executive function performance test to detect executive function deficits at the acute 
stage of stroke. Work: A Journal of Prevention, Assessment and Rehabilitation, 36 
(4), 405-412. 
 
World Health Organisation (2007). World Health Organisation Global Report on 
Falls Prevention in Older Age. World Health Organisation. 
 
World Medical Association. (2013). Declaration of Helsinki: Ethical Principles for 
Medical Research Involving Human Subjects. The Journal of the American Medical 
Association, 310 (20), 2191-2194. 
 
  71   
 
Yanhong, O., Chandra, M. and Venkatesh, D. (2013). Mild cognitive impairment in 
adult: a neuropsychological review. Annals of Indian Academy of Neurology, 16 (3), 
310-318. 
 
Yantz, C. L., Johnson-Greene, D., Higginson, C. and Emmerson, L. (2010). 
Functional cooking skills and neuropsychological functioning in patients with stroke: 
an ecological validity study. Neuropsychological Rehabilitation, 20 (5), 725-738. 
 
Yen-Chi, Y., Ker-Neng, L., Wei-Ta, C. and Pei Ning, W. (2011). Functional 
disability profiles in amnestic mild cognitive impairment. Dementia and Geriatric 
Cognitive Disorders, 31 (3), 225-232. 
 
Appendix 1: Ethics Application Form 
 72   
 
STANDARD APPLICATION FORM 
 
For the Ethical Review of 
Health-Related Research Studies, which are 
not Clinical Trials of Medicinal Products For 
Human Use as defined in S.I. 190/2004 
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 IF YOUR STUDY IS A CLINICAL TRIAL OF A MEDICINAL 
PRODUCT 
 
 
Title of Study:  
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SECTION G RADIATION - (OPTIONAL) 
 
SECTION H MEDICAL DEVICES - (OPTIONAL) 
 
SECTION I MEDICINAL PRODUCTS / COSMETICS / FOOD AND FOODSTUFFS -         
(OPTIONAL) 
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This Application Form is divided into Sections. 
*Sections A, B, C, D, E, J and K are Mandatory. 
 
(Sections F, G, H, I and L are optional.  Please delete Sections F, G, H, I and L if 
these sections do not apply to the application being submitted for review.) 
 
IMPORTANT NOTE:  Please refer to Section I within the form before any attempt 
to complete the Standard Application Form.  Section I is designed to assist 
applicants in ascertaining if their research study is in fact a clinical trial of a 
medicinal product. 
 
IMPORTANT NOTE:  This application form permits the applicant to delete 
individual questions within each section depending on their response to the 
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question.   
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PLEASE ENSURE TO REFER TO THE ACCOMPANYING GUIDANCE 
MANUAL 
WHEN COMPLETING THIS APPLICATION FORM. 
 
SECTION A:  GENERAL INFORMATION  
 
SECTION A IS MANDATORY 
 
A1 Title of the Research Study: 
 
The Relationship between Performance on Cognitive Screening Tools and 
Functional Abilities in Individuals with Dementia 
 
A2 (a) Is this a multi-site study?   No 
 
If you chose ‘yes’ please delete questions A2 (e) and (f), If you chose ‘no’ 
please delete Questions A2 (b) (c) and (d) 
 
A2 (e) If no, please name the principal investigator with overall responsibility 
for the conduct of this single-site study. 
 
Title:  Dr. Name: Joseph Duggan  
Qualifications: MD, FRCPI  
Position: Consultant Geriatrician 
Department: Medicine for the Elderly 
Organisation: Mater Misericordiae University Hospital 
Address: Division of Medicine, Mater Misericordiae University Hospital, Eccles 
Street, Dublin 7 
Tel: 01-8034242 E-mail: jduggan@mater.ie 
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A2 (f) For single-site studies, please name the only site where this study will take 
place. 
Mater Misericordiae University Hospital (MMUH) 
 
A3.  Details of Co-investigators: 
 
Name of site (if applicable): Mater Misericordiae University Hospital 
Title: Ms.  Name: Elaine Scally  
Qualifications: B.Sc in Occupational Therapy, NUI Galway 
Position: Senior Occupational Therapist 
Department : Occupational Therapy 
Organisation: Mater Misericordiae University Hospital 
Address: Occupational Therapy Department, Mater Misericordiae University 
Hospital, Eccles Street, Dublin 7 
Tel: 01-80341115 E-mail: escally@mater.ie 
Role in Research:  Lead Co-Investigator 
 
Name of site (if applicable): N/A 
Title: Dr.  Name: Helen French 
Qualifications: PhD (NUI, RCSI), MSc, Dip Stat, B.Physio, MISCP 
Position: Lecturer in Physiotherapy 
Department: School of Physiotherapy 
Organisation: Royal College of Surgeons in Ireland 
Address: 123 St. Stephen’s Green, Dublin 2, Ireland 
Tel: 01-4022258 E-mail: hfrench@rcsi.ie 
Role in Research:  Co-Investigator/MSc Supervisor 
 
Name of site (if applicable): N/A 
Title: Dr.  Name: Tadhg Stapleton 
Qualifications: PhD (TCD), M.Sc. (Rehabilitation and Research), B.Sc. (Hons.) 
(Curr. Occ) 
Position: Assistant Professor (Occupational Therapy) 
Department: Discipline of Occupational Therapy 
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Organisation: Trinity College Dublin 
Address: Trinity Centre for Health Sciences, St. James’s Hospital, St. James’s 
Street, Dublin 8 
Tel: 01-8963214  E-mail: Tadhg.Stapleton@tcd.oe 
Role in Research: Co-Investigator 
 
A4.  Lead contact person who is to receive correspondence in relation to this 
application or be contacted with queries about this application.  
 
Name: Elaine Scally 
Position: Senior Occupational Therapist 
Organisation: Mater Misericordiae University Hospital 
Address for Correspondence: Occupational Therapy Department, Mater 
Misericordiae University Hospital, Eccles Street, Dublin 7 
Tel (work): 01-8034115 Tel (mob.): 086-1610024 E-mail: 
escally@mater.ie 
 
A5 (a) Is this study being undertaken as part of an academic qualification? 
Yes    
 
If answer is No, please delete remaining questions in Section A 
 
A5 (b) If yes, please complete the following: 
Student Name(s): Elaine Scally  
Academic Course: MSc in Neurology and Gerontology 
Academic Institution: Royal College of Surgeons in Ireland  
 
A5 (c) Academic Supervisor(s): 
 
Title:  Dr. Name: Helen French 
Qualifications: PhD (NUI, RCSI), MISCP 
Position: Lecturer in Physiotherapy 
Department: School of Physiotherapy 
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Organisation: Royal College of Surgeons in Ireland 
Address: 123 St. Stephen’s Green, Dublin 2, Ireland 
Tel: 01-4022258  E-mail: hfrench@rcsi.ie 
 
SECTION B : STUDY DESCRIPTORS 
 
SECTION B IS MANDATORY 
 
B1.   What is the anticipated start date of this study? 
October 2015, pending MMUH Research Ethics Committee approval. 
 
B2.   What is the anticipated duration of this study? 
Six months. 
 
B3.  Please provide a brief lay (plain English) description of the study.  Please 
ensure the language used in your answer is at a level suitable for use in a 
research participant information leaflet. 
Determining how thinking skills affect functional abilities is an important area in 
dementia research. Cognitive tests are commonly used by healthcare professionals to 
assist in making decisions about a person’s ability to perform day to day tasks. 
However, findings from clinical practice show that performance on cognitive tests is 
not always consistent with performance of everyday functional abilities amongst 
individuals with dementia. The aim of this research study is to examine the 
relationship between performance on cognitive tests and everyday functional 
abilities in people with dementia in the acute hospital setting. 
 
B4.   Provide brief information on the study background.  
Dementia is a syndrome that results in progressive deterioration of cognitive abilities 
caused by a number of different disorders (Gifford & Jones, 2009; Sheehan, 2012). 
The cognitive deficits in dementia are not confined to memory and may include 
impairments in language, praxis, attention, information processing and executive 
functions (Farias et al., 2003; Gifford & Jones, 2009; Weintraub et al., 2012). In 
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addition to cognitive deterioration, individuals with this disease also experience 
difficulty in completing activities of daily living (ADLs) such as meal preparation 
and managing finances (De Paula & Malloy-Diniz, 2013; Luttenberger et al., 2012; 
Wajman et al., 2014). 
 
Occupational therapists (OTs) working in the acute care setting are routinely asked 
to make inferences regarding the ability of patients with dementia to complete 
various instrumental activities of daily living (IADLs) including cooking, shopping, 
paying bills and medication management (Borbasi et al., 2006). Cognitive screening 
tools such as the Montreal Cognitive Assessment (MoCA) and the Addenbrooke’s 
Cognitive Examination (ACE-III) are regularly administered by acute hospital OTs 
to assist in predicting the functional capacity of this client group. The relationship 
between cognitive and functional domains in dementia has been investigated in a 
number of studies (Baum et al., 1995; De Paula & Malloy-Diniz, 2013; Farias et al., 
2003; Perry & Hodges, 2000) which have predominately yielded modest results, 
with neuropsychological performance generally accounting for moderate amounts of 
variance in function.  
 
Previous studies investigating the relationship between cognitive and functional 
status in dementia populations share several limitations e.g. use of a wide variety of 
neuropsychological batteries which makes comparison between studies difficult, use 
of informant-based or self-report functional assessments and use of heterogeneous 
elderly patient populations. 
 
The current study aims to extend the findings of previous research pertaining to the 
relationship between cognitive and functional domains in dementia. To address the 
limitations of previous studies, the current study will employ a performance-based 
measure of functional status (Executive Function Performance Test - EFPT) that is 
weighted towards cognitively-orientated IADLs.  Cognitive screening tools that are 
routinely administered in OT practice within the acute care setting will be used to 
assess participants’ neuropsychological status. 
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B5.    List the study aims and objectives. 
The aim of the study is to examine the relationship between performance on 
cognitive screening tools and functional abilities in individuals with dementia.  
 
The objectives of the study are as follows: 
- To determine which particular cognitive screening tool (MoCA or ACE-III) is most 
strongly associated with participants’ functional abilities. 
- To establish which specific cognitive domains are most strongly related to 
participants’ functional abilities. 
- To examine the impact of various demographic factors on participants’ functional 
abilities. 
 
B6.    List the study endpoints / measurable outcomes (if applicable).  
The results of the statistical analyses will be used to establish the relationship 
between performance on cognitive screening tests and functional abilities in 
individuals with dementia.  
 
B7.   Provide information on the study design. 
The study will use an observational cross-sectional study design to examine the 
relationship between performance on cognitive screening tool and functional abilities 
in individuals with dementia in the acute care setting. The Strengthening the 
Reporting of Observational Studies in Epidemiology (STROBE, von Elm et al., 
2008) Statement was reviewed when developing the research design.  
 
B8.   Provide information on the study methodology. 
Pilot Study: 
A pilot study will be completed prior to the main study. Two participants will be 
recruited and assessed by the lead co-investigator for the purpose of the pilot study. 
This will allow the lead co-investigator to estimate the amount of time required to 
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collect data, to test the outcome measures, to trial the data collection form and to 
identify unforeseen limitations to the research design. 
 
Main Study: 
Assessment Procedure: 
Demographic and baseline clinical information will be obtained from the 
participants’ medical records by the lead co-investigator. This information will be 
recorded in the data collection form. The lead co-investigator will administer all of 
the assessment measures which will include the MoCA, the ACE-III and the EFPT. 
It is anticipated that training in administering and scoring the assessments will not be 
required as the researcher is experienced in using the assessments in her clinical 
work. The cognitive assessments can be administered both on the ward and in the 
OT department whereas the functional assessment can be completed in the OT 
department only. If participants are unable to complete all assessments in the initial 
session due to fatigue, they will be completed the following day. All of the 
assessments will be administered in a standardised order. Administration of the 
MoCA, ACE-III and the EFPT with each patient should take approximately 60-80 
minutes in total. 
 
Data Collection: 
The majority of the data will be collected by the lead co-investigator. OT colleagues 
may complete one of the cognitive screening tests with participants prior to their 
enrollment into the research study as part of routine clinical practice. It is anticipated 
that this will not be a methodological issue as both the MoCA and ACE-III have 
good inter-rater reliability (Sheehan, 2012) and it is expected that there will only be a 
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few days between completion of the cognitive screen by the OT colleague and 
assessment by the lead co-investigator. A specific data collection form has been 
designed to gather demographic variables. The quantitative data collected will be at 
interval and ratio levels. Purpose-designed data extraction tables will be developed 
for recording of the data.  
 
B9.  Provide information on the statistical approach to be used in the analysis of 
your results (if appropriate) / source of any statistical advice.  
Descriptive statistics will be employed to explore the data in relation to the key 
outcomes of interest and other variables such as age, gender, marital status, type of 
dementia, time since dementia diagnosis, social situation and frailty. The relationship 
between performance on cognitive screening tools and functional abilities will be 
computed using Pearson product-moment correlation coefficient test for continuous 
variables, Spearman’s rank ordered test for ordinal data and Chi-squared analysis for 
categorical data. SPSS software package will be employed for all statistical analyses 
The co-investigators and academic supervisor were consulted in establishing the 
statistical approach for the study. A review of medical and psychological scientific 
literature was also used to inform this statistical approach.  
 
B10 (a) Please justify the proposed sample size and provide details of its 
calculation (including minimum clinically important difference).   
The mean number of participants used in other similarly designed studies that 
produced statistically significant results pertaining to the psychometric properties of 
the EFPT with stroke populations (Baum et al., 2008; Cederfeldt et al., 2011; Wolf et 
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al., 2010) was calculated with a mean sample size of n=39. This study aims to have a 
sample size of n=40. 
 
B10 (b) Where sample size calculation is impossible (e.g. it is a pilot study and 
previous studies cannot be used to provide the required estimates) then please 
explain why the sample size to be used has been chosen.   
N/A. 
 
B11. How many research participants are to be recruited in total? 
40. 
 
B12 (a) How many research participants are to be recruited in each study group 
(where applicable)?  Please complete the following table (where applicable). 
N/A. 
 
Name of 
Study Group:  
Name of 
Study Group:  
Name of 
Study Group:  
Name of 
Study Group:  
Name of 
Study Group:  
Dementia 
Group 
Answer Answer Answer Answer 
Number of 
Participants 
in this Study 
Group:  
Number of 
Participants 
in this Study 
Group:  
Number of 
Participants 
in this Study 
Group:  
Number of 
Participants 
in this Study 
Group:  
Number of 
Participants 
in this Study 
Group:  
40 Answer Answer Answer Answer 
 
B12 (b) Please provide details on the method of randomisation (where 
applicable). 
N/A. 
 
B13. How many research participants are to be recruited at each study site 
(where applicable)?  Please complete the following table.  
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Site: Number of Research Participants at 
this site: 
MMUH 40 
 
SECTION C STUDY PARTICIPANTS 
 
SECTION C IS MANDATORY 
 
C1 PARTICIPANTS – SELECTION AND RECRUITMENT 
 
 
C1.1  How will the participants in the study be selected?  
 
The study will use a clinical sample of convenience. Individuals with a presenting 
complaint or background history of dementia who are admitted to the MMUH under 
the care of the General Medicine or Medicine for the Elderly services will be 
considered for study selection. They must be referred to OT and they will be 
screened against inclusion and exclusion criteria.  
 
C1.2  How will the participants in the study be recruited?   
The lead co-investigator’s OT colleagues who work in the General Medicine and 
Medicine for the Elderly services will act as gatekeepers. The gatekeepers will 
review the medical charts of individuals referred to OT services covering these 
clinical areas who have a background medical history of dementia. The gatekeepers 
will notify the lead co-investigator of patients who fulfil the specified inclusion and 
exclusion criteria. The gatekeepers will provide suitable potential participants with 
the participant information leaflet.  
 
C1.3 What are the inclusion criteria for research participants?  (Please 
justify, where necessary)  
*65 years of age and above 
*Inpatients in MMUH within Care of the Older Person or General Medicine service 
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*Referred to OT 
*Diagnosis of dementia 
*Medically stable 
*Willing and able to provide informed consent 
*Living at home and participating in at least one IADL at baseline 
*Able to read and write 
*Able to engage in functional assessment at times of recruitment with maximum 
support of assistance of one due to physical deficits 
 
C1.4 What are the exclusion criteria for research participants? (Please 
justify, where necessary)  
*Delirium 
*Severe auditory or visual impairment that could significantly interfere with testing 
*History of any neurological disease that could affect cognition  
*Significant psychiatric disorder 
*History of alcohol or drug abuse 
*Learning disability 
 
C1.5 Will any participants recruited to this research study be 
simultaneously involved in any other research project?  
Not to my knowledge.   
 
C2 PARTICIPANTS – INFORMED CONSENT 
 
C2.1 (a) Will informed consent be obtained?  Yes  
 
C2.1 (b) If no, please justify. You must provide a full and detailed 
explanation as to why informed consent will not be obtained. 
 
N/A. 
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C2.1 (c) If yes, please outline the consent process in full.  (How will consent 
be obtained, when, by whom and from whom etc.)   
Potential participants will be given a participant information leaflet (PIL) that has 
been developed following recommendations from the literature regarding 
communication strategies for individuals with dementia. This is to ensure the written 
information is as accessible as possible. The gatekeeper will discuss the contents of 
the PIL with every potential participant to facilitate their understanding of the written 
material. Voluntary informed consent will then be obtained from willing participants 
by the lead co-investigator. This consent form has also been developed following 
recommendations from the literature regarding communication strategies for 
individuals with dementia.  This is also to ensure optimal accessibility of the written 
information.  
 
C2.2 (a) Will participants be informed of their right to refuse to participate 
and their right to withdraw from this research study? Yes  
 
C2.2 (b) If no, please justify.   
N/A. 
 
C2.3 (a) Will there be a time interval between giving information and 
seeking consent? Yes  
 
C2.3 (b) If yes, please elaborate. 
A period of 24 hours will be given before consent is sought. 
 
C2.3 (c) If no, please justify and explain why an instantaneous decision is 
reasonable having regard to the rights of the prospective research 
participants and the risks of the study. 
N/A. 
C3 ADULT PARTICIPANTS (AGED 18 OR OVER) - CAPACITY 
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C3.1 (a) Will all adult research participants have the capacity to give 
informed consent?  Yes   
If answer is Yes, please delete remaining questions in Section C3 
 
C4 PARTICIPANTS UNDER THE AGE OF 18 
 
C4.1 (a) Will any research participants be under the age of 18 i.e. Children? 
No 
 
If answer is No, please delete remaining questions in Section C4 
 
 
C5 PARTICIPANTS -  CHECKLIST  
 
C5.1 Please confirm if persons from any of the following groups will participate 
in this study.  This is a quick checklist to assist research ethics committee 
members and to identify whether study participants include persons from 
vulnerable groups and to establish what special arrangements, if any, have been 
made to deal with issues of consent.  It is recognised that not all groups in this 
listing will automatically be vulnerable or lacking in capacity.  Please refer to 
the HSE’s National Consent Policy, particularly Part 3, Section 5. 
 
Committees are particularly interested to know if persons in any of these 
groups are being targeted for inclusion, as per the inclusion criteria.  
 
(a) Healthy Volunteers No 
 
(b) Patients Yes  
 
 Unconscious patients  No 
 Current psychiatric in-patients No 
 Patients in an emergency medical setting No 
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(c) Relatives / Carers of patients No  
 
(d) Persons in dependent or unequal relationships No 
 
 Students No 
 Employees / staff members No 
 Persons in residential care No 
 Persons highly dependent on medical care No   
 
 
(e) Intellectually impaired persons No 
(f)  Persons with a life-limiting condition   Yes  
(Please refer to guidance manual for definition) 
(g) Persons with an acquired brain injury   Yes  
 
 
C5.2 If yes to any of the above, please comment on the vulnerability of the 
research participants, and outline the special arrangements in recognition of 
this vulnerability (if any). 
The patient’s capacity to decide to take part in this study will be determined on a 
case-by-case basis. The gate keepers are qualified OTs whose clinical work involves 
assessing the cognitive functioning of patients with dementia. The gate keeper will 
determine that potential participants have sufficient attention, working memory and 
decision making skills at the time of applying the inclusion and exclusion criteria 
and when meeting potential participants to provide them with information on the 
study and the study’s information leaflet. The gate keeper will also liaise with the 
patient’s medical team to ensure that the patient has the capacity to provide informed 
consent for study participation. 
 
In cases of doubt, the gate keeper will determine the answer of all four of the 
questions below is positive before concluding that the patient has capacity: 
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1) Does the patient understand the information relevant to the decision? 
2) Has the patient retained the information relevant to the decision? 
3) Can the patient use of weigh up the information when making a decision? 
4) Can the patient communicate their decision by some reliable means? 
 
In patients where the answer to one or more of the above questions is negative or 
uncertain it will be determined if the reason for this is due to lack of capacity. If the 
reason for apparent lack of capacity is found to be a cognitive impairment, the 
patient will not be deemed capable of providing informed consent and will not be 
included in the study.  
 
C5.3 Please comment on whether women of child-bearing potential, 
breastfeeding mothers, or pregnant women will be included or excluded in 
this research study. 
   
No. 
 
SECTION D RESEARCH  PROCEDURES 
 
SECTION D IS MANDATORY 
 
D1 (a) What activities, procedures or interventions (if any) are research 
participants asked to undergo or engage in for the purposes of this research 
study? 
Participants will be assessed using the MoCA, the ACE-III and the EFPT. It is 
relevant to note that administration of cognitive screening tests and the direct 
observation of patients completing activities of daily living are essential components 
of OT routine practice in dementia care. The data analysis of scores obtained on all 
measures is over and above routine care. 
 
D1 (b) What other activities (if any) are taking place for the purposes of this 
research study e.g. chart review, sample analysis etc? 
Appendix 1: Ethics Application Form 
 89   
 
The lead co-investigator will review patients’ medical records (hard copy and 
electronic) as part of this research study.  
 
D2.  Please provide details below of any potential harm that may result from 
any of the activities, procedures, interventions or other activities listed 
above. 
The non-serious harm of having to undergo the assessment measures may cause a 
minor inconvenience to the participants.  
 
D3.  What is the potential benefit that may occur as a result of this study?  
Examining the relationship between performance on cognitive screening tools and 
functional status in individuals with dementia in the acute care setting will facilitate 
optimal provision of OT services to maximise functional recovery and rehabilitation 
outcomes for individuals with dementia.  
 
D4 (a) Will the study involve the withholding of treatment?  
N/A 
 
D4 (b) Will there be any harms that could result from withholding 
treatment?  N/A 
 
D4 (c) If yes, please elaborate. 
N/A. 
 
D5 (a) How will the health of participants be monitored during the study, 
and who will be responsible for this? 
The monitoring of participants’ health will be in keeping with current practice of 
monitoring patients during OT assessment and intervention. 
 
D5 (b) How will the health of participants be monitored after the study, and 
who will be responsible for this? 
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The monitoring of participants’ health after the study will be in keeping with current 
practice of the medical monitoring patients’ health as appropriate in the acute care 
and community settings. 
 
D6 (a) Will the interventions provided during the study be available if 
needed after the termination of the study?  Yes  
 
D6 (b) If yes, please state the intervention you are referring to and state who 
will bear the cost of provision of this intervention? 
If the participants’ scores on either the cognitive or functional assessment indicate 
deficits, they will receive OT interventions designed to address this aspect of their 
rehabilitation. 
 
D7.  Please comment on how individual results will be managed.  
As the assessment procedures will be part of usual OT service provision, results will 
be recorded on the Hospital Information System (HIS) and Patient Centre and will be 
shared with the patients as part of their intervention planning. Results will also be 
shared with the participant’s treating OT so that they can be used as part of the 
patient’s intervention.  
 
D8.  Please comment on how aggregated study results will be made 
available. 
Results of study findings will be collated and written up as an MSc thesis submission 
to the Royal College of Surgeons in Ireland (RCSI). Upon study completion, the 
participants will be invited to attend an oral presentation along with any interested 
MMUH staff members.  
 
It is also aimed that this study’s findings will be submitted for publication in a peer-
reviewed journal e.g. British Journal of Occupational Therapy or Age and Ageing. 
Findings will also be submitted for oral presentation at relevant national conferences 
e.g. the Irish Gerontological Society Postgraduate Study Day, the annual Association 
of Occupational Therapists in Ireland conference. 
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D9.  Will the research participant's general practitioner be informed that 
the research participant is taking part in the study (if appropriate)?  No  
 
D10.  Will the research participant's hospital consultant be informed that 
the research participant is taking part in the study (if appropriate)?  Yes.  
 
SECTION E DATA PROTECTION 
 
SECTION E IS MANDATORY 
 
 
E1  DATA PROCESSING - CONSENT 
 
E1.1 (a)  Will consent be sought for the processing of data? Yes  
 
E1.1 (b) If no, please elaborate.   
 
N/A. 
 
 
E2 DATA PROCESSING - GENERAL 
 
E2.1  Who will have access to the data which is collected?  
The principal investigator (Dr Joseph Duggan) and the co-investigators (Ms Elaine 
Scally, Dr Helen French and Dr Tadhg Stapleton) will have access to the data which 
is collected. 
 
E2.2  What media of data will be collected? 
Data pertaining to the participant’s demographics will be coded numerically 
according to the order of recruitment into the study and will be stored electronically. 
Numerical data obtained from scores on the research instruments (MoCA, ACE-III 
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and EFPT) will be initially captured on a hard copy that will be destroyed (shredded) 
once data has been entered onto the electronic data extraction tables.  
 
E2.3 (a) Would you class the data collected in this study as anonymous, 
irrevocably anonymised, pseudonymised, coded or identifiable data? 
 
Coded. Numerals will be used to differentiate participants’ demographic 
characteristics and test scores.  
 
E2.3 (b) If ‘coded’, please confirm who will retain the ‘key’ to re-identify 
the data? 
 
Lead co-investigator – Ms Elaine Scally. 
 
E2.4  Where will data which is collected be stored? 
The data which has been collected will be stored on the workplace password 
protected PC that has been encrypted by the MMUH Information Management 
Services department. This PC is situated in the OT department. 
 
E2.5   Please comment on security measures which have been put in place to 
ensure the security of collected data. 
The PC is password-protected and has been encrypted by the Information 
Management Service department at the MMUH. An encrypted USB key will be used 
to transfer electronic data, where it will be stored by the academic supervisor located 
in the RCSI as per this College’s protocol.  
 
E2.6 (a) Will data collected be at any stage leaving the site(s) of origin?     
Yes  
 
E2.6 (b) If yes, please elaborate. 
As per the MMUH protocol, the electronic data obtained from assessment scores will 
be securely stored for a period of five years. 
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E2.7   Where will data analysis take place and who will perform data 
analysis (if known)? 
Data analysis will take place using the encrypted PC in the MMUH OT department. 
The lead co-investigator will perform the data analysis. 
 
E2.8 (a) After data analysis has taken place, will data be destroyed or 
retained? 
Electronic data will be retained. Hard copies of assessment scoring sheets will be 
destroyed once data has been entered onto the electronic data extraction tables.  
 
E2.8 (b) Please elaborate.  
Data will be stored securely for a period of five years as per the MMUH guidelines. 
 
 
E2.8 (c) If destroyed, how, when and by whom will it be destroyed? 
The lead co-investigator will destroy hard data (scoring sheets of MoCA, ACE-III 
and EFPT) via shredding once data has been entered electronically onto the data 
extraction tables.  
 
E2.8 (d) If retained, for how long, for what purpose, and where will it be 
retained?   
Electronic data will be securely stored by the academic supervisor for a period of 
five years as per the MMUH ethics committee guidelines. 
 
E2.9   Please comment on the confidentiality of collected data.  
  
Collected data will be coded. A separate document which will only contain the 
participants’ names and ID numbers will be stored on an encrypted password 
protected computer in the OT department at the MMUH. All clinical data pertaining 
to the participant will contain the ID number only and contain no identifiable details 
such as name, address or date of birth.    
Appendix 1: Ethics Application Form 
 94   
 
E2.10 (a) Will any of the interview data collected consist of audio recordings 
/ video recordings? No 
 
E2.10 (b) If yes, will participants be given the opportunity to review and 
amend transcripts of the tapes? 
N/A. 
 
E2.11 (a) Will any of the study data collected consist of photographs/ video 
recordings?  No 
 
E2.11 (b) If yes, please elaborate. 
N/A. 
 
E3 ACCESS TO HEALTHCARE RECORDS 
 
E3.1 (a) Does the study involve access to healthcare records (hard copy / 
electronic)?  Yes  
 
If answer is No, please delete remaining questions in Section E3 
 
E3.1 (b) If yes, please elaborate.  
The medical chart and the MMUH Patient Centre and HIS systems will be accessed 
by the lead co-investigator for the purpose of applying the inclusion and exclusion 
criteria to potential participants and in order to collect demographic characteristics. 
Specific data to be sought will include reports of any neuroimaging that have been 
completed to investigate the diagnosis of dementia and the patient’s past medical 
history and history of presenting complaint. Healthcare records will be read and 
contributed to in accordance with standard data gathering and documentation 
procedures as part of routine OT service provision within the MMUH. 
 
E3.1 (c) Who will access these healthcare records? 
The lead co-investigator. 
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E3.1 (d) Will consent be sought from patients for research team members to 
access their healthcare records?  Yes  
 
If answer is Yes, please delete remaining questions in Section E3 
 
E3.2 (a) Who or what legal entity is the data controller in respect of the 
healthcare records? 
MMUH Board. 
 
E3.2 (b) What measures have been put in place by the data controller which 
may make access to healthcare records permissible without consent? 
The lead co-investigator  is an employed staff member of the MMUH. The lead co-
investigator is bound by confidentiality via the terms of her employment contact 
with the MMUH and via the code of professional conduct specified in the 
Association of Occupational Therapists of Ireland’s Code of Professional Conduct. 
 
SECTION F HUMAN BIOLOGICAL MATERIAL 
 
F1 BODILY TISSUE / BODILY FLUID SAMPLES - GENERAL 
 
F1 1 (a) Does this study involve human biological material? No 
 
If the answer is No, please delete Section F 
 
SECTION G RADIATION 
 
G1   RADIATION – GENERAL  
 
G1.1  (a) Does this study/trial involve exposure to radiation?  No 
 
If answer is No, please delete remaining questions in Section G 
 
Appendix 1: Ethics Application Form 
 96   
 
SECTION H  MEDICAL DEVICES 
 
H1 (a) Is the focus of this study/trial to investigate/evaluate a medical 
device? No 
 
If answer is No, please delete remaining questions in Section H. 
 
SECTION I MEDICINAL PRODUCTS / COSMETICS / FOOD AND 
FOODSTUFFS 
 
I.1 NON-INTERVENTIONAL TRIALS OF MEDICINAL 
PRODUCTS 
 
I1.1 (a)  Does this study involve a medicinal product? No 
 
If the answer is No, please delete remaining questions in subsection I1 
 
I.2 COSMETICS 
 
I2.1 (a)  Does this study involve a cosmetic? No 
 
If the answer is No, please delete remaining questions in subsection I2 
 
I.3 FOOD AND FOOD SUPPLEMENTS 
 
I3.1 (a) Does this study involve food or food supplements?  No 
 
If the answer is No, please delete remaining questions in subsection I3 
 
SECTION J INDEMNITY AND INSURANCE  
 
SECTION J IS MANDATORY 
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J1 Please confirm and provide evidence that appropriate 
insurance/indemnity is in place for this research study at each site. 
The site in which this study is to take place (MMUH) is covered by the Clinical 
Indemnity Scheme. 
 
J2 Please confirm and provide evidence that appropriate 
insurance/indemnity is in place for this research study for each investigator. 
The principal investigator (Dr Joesph Duggan) and the lead co-investigator (Ms 
Elaine Scally) are covered by the Clinical Indemnity Scheme in the MMUH. Co-
investigators Dr Helen French and Dr Tadhg Stapleton are covered by Indemnity 
Insurance in the Royal College of Surgeons in Ireland and Trinity College Dublin 
respectively. 
 
J3.1   Please give the name and address of the organisation / or individual 
legally responsible for this research study?   
RCSI. 
 
J3.2  Where an organisation is legally responsible, please specify if this 
organisation is: 
 
A pharmaceutical company   No 
A medical device company  No 
A university Yes  
A registered charity  No 
Other  No    If yes, please specify:  N/A 
 
J3.3 Please confirm and provide evidence of any specific additional 
insurance / indemnity arrangements which have been put in place, if any, by 
this organisation / or individual for this research study? 
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Additional insurance/indemnity arrangements are not required. Any unforeseen 
event that results in harm to a participant as a result of involvement in the study is 
covered by the Clinical Indemnity Scheme. 
 
SECTION K COST AND RESOURCE IMPLICATIONS, 
FUNDING AND PAYMENTS  
 
SECTION K IS MANDATORY 
K1 COST AND RESOURCE IMPLICATIONS  
 
K1.1 Please provide details of all cost / resource implications related to this 
study (e.g. staff time, office use, telephone / printing costs etc.)  
The main costs associated with this research project are that of study equipment and 
materials – stationery, photocopying, and use of computer. 
 
K2 FUNDING 
K2.1 (a) Is funding in place to conduct this study?  No 
 
K2.1 (b) If no, has funding been sought to conduct this study?  From where? 
Please elaborate. 
Funding has not been sought to conduct this study.  
 
K2.1 (c) If yes, please state the source 
of funding (industry, grant or other), 
the name of the funder, the amount of 
funding and duration of funding. 
Source of funding 
(industry, grant or other): 
N/A 
Name of Funder: 
N/A 
Amount of Funding: 
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N/A 
Duration of Funding 
N/A 
 
K2.1(d)  Please provide additional details in relation to management of 
funds. 
 
N/A 
 
K2.1(e)  Is the study funded by a ‘for profit’ organisation? No 
 
K2.2 (a) Do any conflicts of interest exist in relation to funding or potential 
funding?  N/A  
 
K2.2 (b) If yes, please elaborate. 
 
N/A 
 
K3 PAYMENTS TO INVESTIGATORS 
 
K3.1 (a) Will any payments (monetary or otherwise) be made to investigators? 
No 
 
K3.1 (b) If yes, please provide details of payments (including amount).  
N/A 
 
K4 PAYMENTS TO PARTICIPANTS 
 
K4.1 (a) Will any payments / reimbursements (monetary or otherwise) be made 
to participants?  No 
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K4.1 (b) If yes, please provide details of payments / reimbursements 
(including amount). 
N/A  
 
SECTION L ADDITIONAL ETHICAL ISSUES 
 
 
L1 (a)   Does this project raise any additional ethical issues?  No 
 
If answer is No, please delete remaining questions in Section L. 
 
PLEASE ENSURE THIS APPLICATION FORM IS FULLY COMPLETED 
AS INCOMPLETE SUBMISSIONS WILL NOT BE REVIEWED.  
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PARTICIPANT INFORMATION LEAFLET 
Version 2: 10
th
 August 2015 
 
Title of Study: The Relationship between Performance on Cognitive Screening 
Tests and Functional Abilities in Individual’s with Mild Cognitive Impairment 
 
Lead Investigator: Elaine Scally, Senior Occupational Therapist, Mater 
Misericordiae University Hospital. Email: escally@mater.ie. Tel: 01-8034115 
 
Research Supervisor: Dr. Helen French, Royal College of Surgeons in Ireland. 
Email: hfrench@rcsi.ie. Tel: 01-4022258 
 
You are invited to take part in this research study. This leaflet will tell you about the 
purpose, risks and benefits of the study. Please read it carefully. 
 
If there is anything you are not clear about, the lead investigator will be happy to 
explain it to you. Please take as much time as you need to read it.  
 
If you agree to take part in the study, you will need to sign an informed consent 
document. You should only consent when you feel that you understand what is being 
asked of you and you have had enough time to think about your decision. Your 
participation is entirely voluntary. If you initially decide to take part you can later 
change your mind without difficulty.  
 
Why is this study being done? 
 
This purpose of this study is to look at the relationship between how people with 
cognitive problems perform in cognitive tests and how they perform everyday 
activities. 
 
Who is organising and funding this study? 
 
Elaine Scally, a Senior Occupational Therapist in the Mater Misericordiae University 
Hospital, is carrying out this research. This study is part of a Master’s Degree 
project. Elaine’s supervisor is Dr. Helen French, a Lecturer in at the Royal College 
of Surgeons in Ireland.  
 
Why am I being asked to take part? 
 
You are being asked to take part because you are currently a patient in the Mater 
Misericordiae University Hospital and you have been referred to Occupational 
Therapy to improve your function and ability to do everyday tasks.  
 
How will the study be carried out? 
 
40 people will be taking part in this study. The study will take place on the ward and 
in the Occupational Therapy department. People who decide to take part in the study 
will be required to complete cognitive tests and functional assessments. The study 
will take place between September 2015 and March 2016. 
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What will happen to me if I agree to take part? 
 
People who decide to take part in this study will need to complete cognitive tests and 
functional assessments with the researcher Elaine Scally. This will take 
approximately 60-80 minutes and will be completed over 1-2 sessions. The sessions 
will take place on the ward and in the Occupational Therapy department.  
 
What are the benefits? 
 
It is hoped that the results of this study can be used to ensure that Occupational 
Therapy services are provided in the best possible manner for people with mild 
cognitive impairment. Results from the tests will be provided to your treating 
Occupational Therapist and can be used as part of your treatment planning. 
 
What are the risks? 
 
If you decide to take part in this study it may cause some minor inconvenience to 
you as it will take approximately 60-80 minutes of your time. 
 
Will it cost me anything to take part? 
 
No it will not cost you anything to take part in this study. 
 
Is the study confidential? 
 
All information will be kept confidential. Your current hospital Consultant will be 
informed that you are taking part in the study. The researcher will need to look at 
your medical records in the chart and on the computer. All information collected 
from the assessments will be coded. This means a code number will be assigned to 
all of your identifiable personal information to protect confidentiality.  The lead 
investigator is the only person who will have the key to this code. 
 
Where can I get further information? 
 
If you have any further questions about the study or if you want to opt out of the 
study, you can rest assured it won't affect the quality of treatment you get in the 
future.  If you need any further information now or at any time in the future, please 
contact:  
 
Name: Elaine Scally                  Phone: 01-8034115 (Monday – Friday 08.30-16.30) 
 
Address:  Occupational Therapy Department, Mater Misericordiae University 
Hospital, Eccles Street, Dublin 7  
 
 
 
THANK YOU FOR CONSIDERING TO TAKE PART IN THE RESEARCH 
STUDY
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CONSENT FORM 
Version 2: 10
th
 August 2015 
 
Title of Study: The Relationship between Performance on Cognitive Screening 
Tests and Functional Abilities in Individual’s with Mild Cognitive Impairment 
 
Lead Investigator: Elaine Scally, Senior Occupational Therapist, Mater 
Misericordiae University Hospital. Email: escally@mater.ie. Tel: 01-8034115 
 
Research Supervisor: Dr. Helen French, Royal College of Surgeons in Ireland. 
Email: hfrench@rcsi.ie. Tel: 01-4022258 
 
I have read and understood the Information Leaflet dated 
10/08/2015 about this research project.  The information has been 
fully explained to me and I have been able to ask questions, all of 
which have been answered to my satisfaction. 
 
Yes  No  
I understand that I don’t have to take part in this study and that I can 
withdraw from the study at any time.  I understand that I don’t have 
to give a reason for withdrawing from the study and I understand 
that withdrawal from the study won’t affect my future medical care. 
 
Yes  No  
I give permission for researchers to look at my medical records to 
get information.  I have been assured that information about me will 
be kept private and confidential.  
 
Yes  No  
I have been given a copy of the Information Leaflet and this 
completed Consent Form for my records. 
 
Yes  No  
I agree to take part in the above research study. 
 
Yes  No  
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Participant’s Name (BLOCK CAPITALS):   _____________________________ 
Participant’s Signature:                                    _____________________________ 
Date:                                                                _____________________________ 
 
Researcher’s Name (BLOCK CAPITALS):   _____________________________ 
Researcher’s Signature:                                    _____________________________ 
Date:                                                                _____________________________ 
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Data Collection Form 
 
 
Participant Number:   
Age:  
Nationality:  Irish □    
Other (write in) □  ______________ 
Gender:    Male □      
Female □ 
 
Reason for Admission to MMUH:  
Recruitment Source: Care of the Older Person □ 
General Medicine □ 
Self-Reported Cognitive Impairment:   Yes □     No □ 
 
Co-morbidities: 
    
    
    
 
Medications: 
    
    
    
 
Highest Educational Achievement: Primary Level:   □ 
Secondary Level:   □ 
Third Level:   □ 
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Marital Status: Single:   □ 
Married:   □ 
Widowed:   □ 
Divorced/ Separated:   □ 
 
Living Situation: Lives alone:   □ 
Lives with spouse:   □ 
Lives with offspring:   □ 
Lives with sibling: □ 
Other: □ 
 
Clinical Assessment Scores: 
Executive Function Performance Test Total Score: 
 Cooking: 
 Telephone Usage: 
 Medication Management: 
 Bill Payment: 
 
 Initiation: 
 Organisation: 
 Sequencing: 
 Judgement and Safety: 
 Completion: 
 
Montreal Cognitive Assessment Total Score: 
 Visuospatial/ Executive:  
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 Naming: 
 Attention: 
 Language: 
 Abstraction: 
 Delayed Recall: 
 Orientation: 
 
Addenbrooke’s Cognitive Examination Total Score: 
 Attention: 
 Memory: 
 Fluency: 
 Language: 
 Visuospatial: 
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